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ABSTRACT 
In recent years polyol containing chiral γ-butyro and δ-valerolactones have attracted much 
attention due to their importance as building blocks in natural product synthesis and their 
various biological activity profiles. Thus, employing these lactone moieties in the design and 
construction of newly isolated natural products significantly contributes to the enrichment of 
the existing pool of known biologically active substances.  Most of these five- and six-
membered ring lactones are formed relatively easily from the respective hydroxy acids. We 
describe an efficient and highly flexible stereoselective total synthesis of the respective chiral 
γ- and δ-lactones musacin F and catenioblin B (14.0% and 7.7% overall yield). This work 
presents the first total synthesis of catenioblin B via a titanium(IV) mediated regioselective 
epoxide ring-opening of the epoxy alcohol and includes named reactions such as Grignard and 
Luche reduction reactions to give a hydroxy acid intermediate that, then undergoes a 
TEMPO/BAIB mediated intramolecular cyclization as the key steps in good yields. Similarly 
the structurally related musacin F was also synthesized utilising a Sharpless asymmetric 
dihydroxylation, Grignard, Luche reduction and acid catalyzed intramolecular cyclization 
reactions. 
Besides the synthesis of catenioblin B and musacin F, it was of interest to prepare and 
investigate the medicinal applications of various 2,4,6-trisubstited polyphenol-1,3,5-triazine 
as inhibitors of Aβ-aggregation in Alzheimer’s disease (AD). AD is a neurodegenerative 
disorder characterized by progressive and irreversible impairment of memory and other 
cognitive functions. Previous reports suggested that pathological deterioration of AD patients 
has been associated with extra cellular cerebral accumulation of insoluble aggregates of 
xix 
 
amyloid-β peptides (Aβ) and intracellular hyperphosphorylated and tangled tau protein. 
Although the Aβ-modulating agents are in development, however there is no cure for AD and 
many drugs have failed in recent clinical trials. In order to tackle the problem, effective 
therapeutic and preventive interventions should be developed urgently. Therefore, treatment 
for AD research emphasize on development of drugs that can simultaneously perform 
multiple tasks such as reducing inflammation, preventing of Aβ and tau aggregation. 
Polyphenols 1,3,5-triazines exhibit an extensive range of pharmacological activities including 
potent anticancer properties. Based on literature reports we also investigated their cytotoxicity 
and antioxidant properties. Chapter IV describes the preparation of some 2,4,6-trisubstited 
polyphenol s-triazine hybrid derivatives, their cell viability against Aβ toxicity monitored by 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assays, and their 
cytotoxic activity evaluation in three human cancer cell lines including antioxidant properties. 
Among the tested, compounds, s-triazines with pendent aromatic hydroxy groups exhibited 
potent biological activities. Their simple synthetic preparation and biological properties make 
these 2,4,6-trisubstited polyphenol s-triazine scaffolds promising new entities for the 
development of new drugs with diverse therapeutic applications. 
 
 
 
 
 
  
 
 
 
 
CHAPTER-I 
INTRODUCTION OF γ-BUTYROLACTONES AND δ-VALERO LACTONES IN 
NATURAL PRODUCTS   
                                                                                                                               Chapter I 
 
 
1 
1.1 INTRODUCTION 
Natural products are chemical compounds found in nature that are normally either 
of prebiotic sources from microbes, plants, or animal-origin.  They are not accidently 
produced in nature, but more likely stem from a natural evolution of the increase in cellular 
organism complexity. Throughout the ages, nature has provided humankind with the 
production of natural products for use as food, shelter, clothing, means of transportation, 
fertilizers, flavors, fragrances, and last but not least, medicines, for basic needs and also as 
raw materials for the first generation of therapeutic substances.1 Plants have been the 
sources for traditional medicines that have existed for thousands of years. The first 
recorded use of natural products on the medicinal purposes was written on hundreds of clay 
tablets in cuneiform came from Mesopotamia dating back to around 2600 BC. As a 
testament of to their importance to humans, many of these plant-derived substances are still 
in use today as treatments for influenza, inflammation, coughing, parasitic infection and 
ailments from coughs and colds.2 
Natural products serve as a promising major source for drug discovery and are 
widely recognized in the pharmaceutical industry due to their structural diversity and broad 
range of pharmacological activities.3 Accordingly, they represent very useful tools for 
pharmacologists and biologists, and function as lead compounds for the treatment of 
hypercholesterolemia, inflammation, microbial infections, cancer, and tissue rejection after 
organ transplantation. Biologically active natural products produced by plants, animals, 
insects, fungi, bacteria and protozoans have been isolated and used for pharmaceutical drug 
discovery and design. 
 Five- and six-membered saturated cyclic esters, such as γ-butyrolactones and δ-
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2 
valerolactone, (Figure 1.1) moieties contribute prominent part structures of important 
compounds.4 Thus, employing these lactone moieties in the design and construction of new 
natural product like compounds may significantly enrich the existing pool of known 
biologically active substances. 
 
       Also, functionalized γ- and δ-lactones have served as key intermediates in the 
synthesis of natural products, including alkaloids, terpenoids,  lignan lactones, macrocyclic 
antibiotics, pheromones, perfumeries, polyketides and in biologically active compounds 
such as anti-tumor, anti-depressant, anti-bacterial, anti-microbial and anti-viral agents.5 
Most of these lactones are chiral and the physiological activity often depends on their 
absolute configuration.6 
1.2 The molecular structures and biological activities of some natural products 
containing a γ-butyrolactone scaffold  
(-)-Cis and (+)-trans whisky lactones and (-)-cis and (+)-trans cognac lactones are often 
referred as Quercus lactones. These lactones have been isolated from different types of 
wood and have been identified as key flavors of aged alcoholic beverages such as whisky, 
brandy and wine.7 The molecular structures and biological activities of some natural 
products containing a γ-butyrolactone scaffold system are depicted in scheme 1.1.  
 
                                                                                                                               Chapter I 
 
 
3 
 
Table 1.1 Examples of natural products containing the γ-butyrolactone ring system 
S.No 
Structure Isolation and Biological activity 
1 
 
(–)-Muricatacin commonly known as ‘sour sop’ or 
‘guanabana’. McLaughlin et al., in 1991 were 
isolated from the seeds of the tropical evergreen 
Annona muricata L. (Annonaceae) and exhibits 
potent cytotoxicity towards animal and human 
tumour cell lines KB EC50 = 5µg/mL and VERO 
EC50 = 10µg/mL.
8 
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2 
 
Hydroxylated lactones are produced by the male 
jewel wasp, Nasonia vitripennis, a parasitoid of 
flies. It is a mixture of (4R,5R)- and (4R,5S)-5-
hydroxy-4-decanolide,9 which is deposited on 
surface by the wasp.10 These specific sex  male 
pheromone serves as an indicator of full sperm 
load, favouring acceptance by the female.11  
3 
 
Sofosbuvir is a nucleotide analogue, used in 
combination with other drugs, for the treatment of 
hepatitis C virus (HCV) infections. It inhibits 
the RNA polymerase that the hepatitis C virus uses 
to replicate its RNA. It was 
discovered and developed by pharmacists at Gilead 
Sciences.12 
4 
 
Wei et al., in 2006 isolated Polyporolide from the 
mycelial solid cultures of Polyporus, strain 
SC0652.13 This strain possesses antibacterial 
activity towards Escherichia coli. and also exhibits 
toxicity towards brine shrimp14 (Artemia salina) 
with a LC50 value of 424.5 μg mL-1.  
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5 
 
Yue-Hu Pei et al., in 2009 isolated 1-(5-
oxotetrahydrofuran-2-yl)ethyl 2-phenylacetate from 
the fungus Nigrospora sphaerica.15 No activity 
reported for this molecule. 
6 
 
Sapinofuranone A and B are 5-substituted 
dihydrofuranones, which were isolated by Antonio 
Evidente et al., in 1999 from phytopathogenic 
fungus, Sphaeropsis sapinea.16 
 Antonio Evidente et al., in 2015 also isolated  
Sapinofuranone C from culture filtrates of a 
Diplodia corticola strain.17  
7 
 
 Pilocarpine is a naturally occurring imidazole 
alkaloid, which was first isolated independently by 
Hardy and Gerrard in 1875 from the leaves of 
Pilocarpus microphyllus,18 and is commonly used 
for the treatment of glaucoma.19  
8 
 
Yohehara et al., in 1958 isolated both the lactones 
from Streptomyces species. These are antibiotics  
effective against fungi and yeast.20 
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1.3 The molecular structures and biological activities of some natural products 
containing the δ-valerolactone scaffold  
 
1.4 δ-lactones containing an alkyl side chain  
Massoia lactone (Figure 1.2) is an important component of massoia bark oil isolated from 
Cryptocarya massoia,21 and is also present in jasmine flowers, sugarcane stems, and 
Osmanthus fragrance, Hierochloe odorata, and Hierochloe australis oils. It is used as an 
aromatizer in perfumery and in the manufacture of alcoholic drinks and tinctures.22 
Synthetic massoia lactone23 is widely used in the perfume and food industries instead of the 
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natural product in an effort to save natural sources. 
Saturated (R)-δ-decalactone (Figure 1.2) is found in cashew apples (Anacardium 
occidentale L.) and tuberose flowers (Polianthes Tuberosal Amaryllidaceae) it and imparts 
a sweet, mild, and fruity odor.21, 22, 23, 24 It is also used as an additive in the manufacture of 
cheese and butter.  
(+)-3-Hydroxydecano-5-lactone (Figure 1.2) is produced by Cephalosporium recifei and 
inhibits cholesterol-induced accumulation of fat (hypocholesterolemic activity) 22, 25 
 
Prelactones (Figure 1.3) also constitute an important class of highly functionalized chiral δ-
lactones isolated from various polyketide macrolide producing microorganisms and they 
represent the early steps of polyketide biosynthesis pathways en route to complex lactone 
containing natural products. Prelactone C and B were isolated from the mycelium extract of 
Streptomyces species and culture filtrate extract of Streptomyces grises. Prelactone V was 
isolated from the viranamycin producing organism and prelactone E from the strain 
producing the C2 symmetric polyketide–derived macrodiolide elaiophylin.26 
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1.5 Natural products with functionalized γ- and δ-lactones ring and their synthetic 
strategies  
Lactones are cyclic esters of hydroxycarboxylic acids, especially gamma- and delta -
lactones are intramolecular esters of the corresponding hydroxy fatty acids.  The simplest 
synthetic route to producing a cyclic ester ring system is to perform a intramolecular 
reaction on a hydroxy-carboxylic acid under acid catalysis, oxidative cyclisation and by 
ring closing metathesis (RCM) catalysis to produce a lactone. Many gamma- and delta-
lactones are formed readily from the hydroxyl-carboxylic acids and sometimes it is not 
even necessary to add acid or other reagent to catalyze the intramolecular esterification 
reaction. This lactonization process (Scheme 1.3) is an equilibrium reaction that is favored 
if the lactone formed has a five- or six-membered ring.27  
 
Pheromones are signaling substances secreted by an individual and received by a second 
individual of the same species, in order to induce a specific response such as a special 
behavior or a developmental process.28 Their bioactivity often depends on chirality, for 
example, there are cases in which only one enantiomer is bioactive, and the opposite 
enantiomer inhibits the pheromone signelling. Different enantiomers or diastereomers of 
the same substance can be employed by different species, one enantiomer may be active on 
males, while the other is active on females.29  
Derivatives of various lactones play an important role as sex attracting pheromones of 
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different insects and as plant growth regulators.30 Since the late 1960’s chiral or non-
racemic pheromones containing γ- and δ-lactones have been identified. The Japanese 
beetle, Popillia Japonica Newman, is a devastating pest in a variety of trees and crops in 
the United States. Tumlinson et al., (Figure 1.4) have isolated a pheromone from virgin 
female beetles and identified it as (R,Z)-(–)-(1-decenyl)oxacyclopentan-2-one 1.31 Leal et 
al., have isolated pheromone 232 from the female cupreous chafer beetle, Anomala cuprea 
which closely resembles the sex pheromone 1 of Popillic Japonica Newman.33  
 
Therefore, looking for new stereoselective methods of synthesis of the optically pure 
products with various biological activities is one of the most developed areas in current 
chemistry. For example 4-phenyl butyrolactone 3 has been used for the synthesis of (R)-
fluoxetine and (R)-norfluoxetine, that are known to be potent and selective serotonin 
reuptake inhibitors used for the treatment of depression and anxiety.34 4-benzyl-γ-
butyrolactone 4 is a core framework for a variety of naturally occurring lignans, including 
some medicinally important compounds.35 It is a versatile synthetic intermediate for 
pharmacologically active compounds such as platelet aggregation inhibitors, non-steroidal 
anti-progestine and central nervous system active compounds.36 
The utility of these structural subunits is enhanced by the ease of construction and 
functionalization of the lactone ring system. The potent biological profile of these 
compounds compelled many synthetic groups to initiate a program aimed at the synthesis 
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of this unique lactone in both enantiomeric forms from cheap, commercially available 
starting materials such as amino acids, tartaric acid, ascorbic acid, carbohydrates, or 
ribanolactones; from chiral sulfoxides, epoxides, or substituted acetylenic acids; and by 
various enzymatic or synthetic reductions, oxidations, and hydrolysis.37 
          Stereochemically defined γ-butyrolactones frequently serve as key intermediates in 
natural product synthesis, providing pivotal sources of asymmetry in many cases. There are 
a number of natural sources to derive these versatile lactone intermediates and some 
examples are given in Scheme 1.4 using glutamic acid, ribanolactone and malic acids as 
starting materials for the synthesis of a key hydroxymethyl γ-butyrolactone intermediate 
useful chiral building block for several simple/complex natural product synthesis.38 
 
1.5.1 Synthesis of trans β,γ-Disubstituted γ-Butyrolactone 
 
Devalankar et al., (Scheme 1.5) obtained the β,γ-disubstituted γ-butyrolactone, i.e. (+)-
eldanilide by a regioselective ring-opening of chiral epoxide 5b using a Grignard reagent. 
In turn, epoxide 5b was obtained by Jacobsen's hydrolytic kinetic resolution of racemic 
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epoxy ester 5 to enantiomerically pure epoxy ester 5b and the corresponding trans-3,4-
disubstituted γ-butyrolactone 5a instead of diol.39 
 
Toshiyuki et al., (Scheme 1.6) also reported a new approach towards the synthesis of trans 
β,γ-disubstituted γ-butyrolactone, i.e. (+)-eldanilide via intramolecular radical cyclization 
of the butyl acetol 7, which could be prepared from the allyl alcohol 6.40 
 
Shi et al., (Scheme 1.7) report the asymmetric epoxidation of non conjugated cis-olefin i.e. 
(Z)-4-decenoic acid 8 with chiral ketones 9 to form (4R,5S)-5-hydroxy-4-decanolide up to 
91% ee. To explain the obtained ee, it is likely to be derived from hydrophobic interactions 
between the substrate and the catalyst with the hydrophobic n-hexyl group of the olefin 
aligned adjacent to the N-aryl group of the catalyst in the transition state (spiro A favored 
over spiro B).41 
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1.5.2 Iodolactonization 
Iodolactonisation (Scheme 1.8) was first reported by Bougalt and coworkers in 1904 and 
has since become the most effective way to prepare exo orientated γ-lactones instead of 
endo orientation. The mild reaction conditions of NaHCO3 and I2 were used in the presence 
of substituted non conjugated olefins in various solvents.42 
Bartlett and coworkers were able to synthesize cis and trans five membered ring lactones 
by adjusting the reactions conditions including reaction time and temperature (Scheme 
1.9). The cis product was formed under kinetic conditions (short reaction times) while 
the trans product was formed under thermodynamic conditions (relatively longer reaction 
times).43 This method has been used by E. J. Corey for the synthesis of prostaglandins.44 
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1.5.3 Acid-media cyclisation 
Ueki et al., synthesized musacin E isomers from D-erythronolactone, L-tartaric acid and S-
malic acid.45 The absolute stereochemistry of musacins was unambiguously established by 
the synthesis of different isomers (Scheme 1.10). The protected aldehydes 10a, 10b were 
prepared from D-erythronolactone and L–tartaric acid by successive synthetic conversions. 
The trans olefin was synthesized via a Takai reaction, followed by basic hydrolysis 
cyclisation to form compounds 12 and 13. Finally epimerization of the hydroxyl group in 
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12 by a Mitsunobu reaction afforded 14. 
 
Gonzalez et al., (Scheme 1.11) have transformed the commercially available chiral reagent 
D-malic acid into chiral furan 15, setting the stage for the synthesis of five membered ring 
lactones (eg: (-)-muricatacin). 46 Furan 15 was subjected to singlet oxygen oxidation 
followed by a Luche reduction with NaBH4 to give the intermediate hydroxy acid 16 that 
underwent acid catalyzed in situ lactonization followed by catalytic hydrogenation 
affording (-)-muricatacin butyrolactone.47  
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Keck et al., (Scheme 1.12) reported the synthesis of the long alkyl chain δ-lactone. The 
asymmetric allylation of hexanal with the stannane 18 gave compound 19.48 Then 
subsequent ozonolysis of 19, followed by reduction of the reaction mixture, lactonization 
of intermediate hydroxyl esters under acidic conditions, and dehydration by the action of 
methanesulfonyl chloride–triethylamine afforded lactone 20. Massoia lactone 20 was 
smoothly reduced to (R)-decano-5-lactone 21.49  
Takano et al., previously described a two-step procedure as the epoxidation on 22 should 
be reformed over the double bond position of 20 into the hydroxy lactone 23.50 
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1.5.4 δ-lactones from cyclohexenones  
Heathcock et al., (Scheme 1.13) have reported the ozonolysis of octalone 24 in methanol at 
-60 °C, followed by the addition of excess sodium borohydride at 0 oC, to afford the δ-
lactone 26 in 42% yield.51  
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1.5.5 Ring-closure/cross metathesis (RCM) approach for formation of lactones 
Ring closing metathesis (RCM) is a widely used olefin metathesis in organic chemistry for 
the synthesis of various unsaturated rings via the intramolecular metathesis of two 
terminal alkenes, which forms the cycloalkene as the E- or Z-
 isomers and volatile ethylene.52 
 
Quinn et al., (Scheme 1.15) synthesised, both the lactone and the alkyl chain extension was 
accomplished in an efficient one-pot process.53 (R,R)-Hexa-1,5-diene-3,4-diol 27 obtained 
from D-mannitol54 was mono benzylated followed by subsequent acrylation of the 
remaining hydroxyl group to afford acyclic triene 28.55 Next, in the presence of Grubbs 
catalyst I and 1-dodecene, triene 28 undergoes cyclisation and alkyl chain extension in a 
single step, whereupon catalytic hydrogenation afforded (–)-muricatacin.  
 
Ghosal and co-workers claimed (Scheme 1.16) an appropriate precursor or key 
intermediate, butenolide 32 could be accessed from D-ribose.56 Later, by using RCM on 
this butenolide and subsequent hydrogenation afforded [(+)-S, R] epi-muricatacin.  
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Fernandes et al., (Scheme 1.17) developed a synthetic route for a polyporolide structure 
with anti-placement of the three adjoining stereocenters. Initially, esterification of (S)-1-
octen-3-ol 33 with 3-butenoic acid 34 provided diene 35, that after RCM, gave the δ-
lactone 36. Subsequent Sharpless dihydroxylation of olefin 36 using (DHQ)2PHAL ligand 
and in situ trans-lactonization gave polyporolide.57 
 
1.5.6 Synthesis of (–)-(5R,6S)-hexadecanolide  
The natural mosquito attractant pheromone, (–)-(5R,6S)-6-acetoxyhexadecan-5-olide  
(Scheme 1.18) was synthesised via the conversion of a homoallyl alcohol into the 
corresponding acryl ester 37 followed by RCM and hydrogenation to generates the 
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benzyloxy derivative of (5S,6R)-hexadecanolide.58 Then debenzylation and acylation of the 
secondary alcohol afforded (–)-(5R,6S)-6-acetoxyhexadecan-5-olide.   
 
Li et al., (Scheme 1.19) synthesised via an L-proline catalysed asymmetric aldol reaction 
from readily available aldehyde and cyclopentanone followed by a Baeyer–Villiger 
oxidation achieved the preparation of (5S,6R)-hexadecanolide in 96% ee.59 The aldol 
product 38 was isolated as the major diastereomer. 
 
1.5.7 Chemoselective oxidative cyclization reactions to lactones 
Forsyth and co-workers demonstrated (Scheme 1.20) an effective method to 
chemoselectively oxidise 1°, 2°-1,5-diols to highly functionalized δ-lactones with catalytic 
amounts of TEMPO/BAIB at room temperature to prepare a lactones in 77-96% yields.60 
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Chakraborty et al., developed a route for (+)-prelactone C (Scheme 1.21) via radical-
mediated diastereoselective opening of trisubstituted epoxy alcohol 41 at the more 
substituted carbon to give 42 is a key step. For the generation of terminal methyl group 
from the ester 43 DIBAL-H reduction to allylic alcohol was empolyed mesylation and then 
reduction of the mesylate with lithium triethyl borohydride afforded 44 in overall yield 
80% (three steps). Finally acid treatment of the ester 45 deprotected the acetonide ring with 
concomitant cyclization to yield a (+)-prelactone C.61 
 
Hirai et al., developed (Scheme 1.22) the palladium(II)-catalyzed cyclization of 3,7-
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dihydroxy-4-methyl-5-octenal 46 by stereoselective 1,3-chirality transfer to give a 2,3,4,6-
tetrasubstituted tetrahydropyran 47 with net retention of stereochemistry. The cyclized 
product 47 was converted into 5-epi-prelactone C. 62 
  
Another method for formation of stable 5- and 6-membered lactones readily proceeds via 
alkylation of (Scheme 1.23) chiral 1,2-oxiranes with terminally unsaturated Grignard 
reagents and vice versa.63 Subsequent oxidative degradation (OsO4–Oxone) of the terminal 
double bond (Scheme 1.24) of chiral alk-1-en-5-ols and alk-1-en-6-ols affords 4- or 5-
hydroxy acids, will provide γ- and δ-lactones after acidic workup.64 This is the most 
important improvement of the sequence and avoids protective group manipulations. 
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Example  
 
1.5.8 Research strategies for the synthesis of the 1,2,3-polyol segment 
Wang and co-workers showed that (Scheme 1.26) dihydroxylation of unsaturated lactone 
48 under Sharpless asymmetric dihydroxylation conditions gave 2-deoxyribolactone 49 in 
excellent yield >88% and 97% de 65 
 
Radha Krishna and co-workers synthesized and proposed structure of polyporolide via 
asymmetric approach by a titanium(IV) mediated regioselective ring-opening reaction of 
corresponding epoxy alcohol 50 gave the crucial 1,2,3-polyol 51.66 Later, oxidative 
degradation (OsO4–Oxone) of the terminal double bond followed by acid-catalyzed one pot 
deprotective-intramolecular lactonization of compound 52 afforded the final product.  
                                                                                                                               Chapter I 
 
 
23 
 
Radha Krishna et al., reported a tandem conjugate addition–lactonization of (6S,1S,2R)-
hydroxypestalotin (Scheme 1.28), starting with the benzoate ester protected allylic alcohol 
53 and Sharpless asymmetric dihydroxilation protocol gave a diol, which was masked with 
2,2-DMP as the acetonide protected form of 54.67 Next, the deprotection of the benzoyl 
group forms a primary alcohol, which on oxidation followed by Grignard reaction with 
propargyl bromide gave the alkyne derivative 55. Later on, oxidation of the homo 
propargylic alcohol 55 to a ketone was followed by further reduction under Luche 
conditions to afford the 1,2,3-polyol containing structure 56. Then further transformations 
produced LL-P880β.  
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1.6 Conclusions and outlook 
Natural product total synthesis has long fulfilled many roles in synthetic organic chemistry 
and one of the foremost being the inspiration of the development of novel methods and 
strategies to access particular structures. Mainly from the work of Robert Burns 
Woodward, Elias James Corey and Ken-. C. Nicolaou, who were instrumental in the total 
synthesis of many major natural products. The series will be of vital use not only to 
synthetic and process chemists in academia and industry but also to medicinal chemists and 
chemists working in drug discovery. This modularity allowed the synthesis of naturally 
occurring five and six membered lactones. 
1.7 Research objectives towards the synthesis of catenioblin B and musacin F 
The ubiquitous presence of a 1,2,3-polyol segment in many biologically active natural 
products has led to the development of multiple synthetic strategies of the fragment. As a 
consequence, interest in the structures and biological features of polyol containing 
macrolides (Figure 1.5) as appealing synthetic targets has increased.  
Our target molecule Catenioblin B is also architecturally endowed with the same 1,2,3-
polyol moiety. The usual method access these 1,2,3-polyol containing molecules is by 
functional group manipulation of carbohydrates68 but ever since the discovery of Sharpless 
asymmetric epoxidation in 1980,69 ring-opening reactions of enantiopure 2,3-epoxy 
alcohols with various nucleophiles has gained prominence as an alternate synthetic route.  
Interestingly, such ring-opening reactions have been extensively studied (eg. regio- and 
stereo-selective ring opening; oxidation; and reduction).70 Of the many metal-assisted 
intermolecular C3-selective substitution reactions of 2,3-epoxy alcohols, Sharpless 
titanium(IV)-mediated regioselective ring-opening protocol is worth mentioning. So we 
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used this unique synthetic solution for the synthesis of catenioblin B featuring a concise, 
convergent, and highly stereoselective approach to this natural product. 
 
Our interest in δ-lactones arose from studies in which it was demonstrated that the trans-
1,2-diol fragment relevant to catenioblin B could be prepared following our recently used71 
titanium(IV)-mediated regio- and stereoselective C3 epoxide ring-opening reaction of 
chiral epoxy allyl alcohols with acids (Nu-), a reaction tool for the expedient synthesis of 
polyol systems (Scheme 1.29). Herein we disclose a hypothetical formation of highly-
substituted chelate complex with Ti(OiPr)4.
72 
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1.7.1 Sharpless dihydroxylation  
The Sharpless dihydroxylation is used in the enantioselective preparation of 1,2-diols from 
prochiral olefins. This procedure is performed with two commercially available reagent 
kits: Ad-mix-γ and Ad-mix-β and the selectivity of each kit follow the empirical rules 
(Scheme 1.30). In this Ad, stands for asymmetric dihydroxylation. The mix contains 
potassium osmate (K2OsO2(OH)4 ) as the source of osmium tetroxide, K3Fe(CN)6, as a re-
oxidant in the catalytic cycle, potassium carbonate maintain basic reaction conditions and 
proceeds faster and a chiral ligands [(DHQD)2PHAL, (DHQ)2PHAL)] used (Figure 1.6) to 
enrich the enantioselectivity. Along with these catalysts, methanesulfonamide (MsNH2) is 
used as an additive to improve enantioselectivity.73  
By using this synthetic methodology we have generated 1,2-syn diol from α,β-unsaturated 
ester under (AD-mix-β/tBuOH/H2O/0 oC to rt/12 h) conditions, a synthetic tool for the 
practical synthesis of 1,2-diol in 1,2,3-polyol system in musacin F.  
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1.7.2 The Luche reduction of enones  
          The Luche reduction can be used to convert α,β-unsaturated ketones into allylic 
alcohols using CeCl3, NaBH4 and methanol as solvent.
74 The role of the cerium is twofold:  
1) It contributes catalysis of the formation of alkoxyborohydrides.  
2) It increases the electrophilicity of the carbonyl carbon atom by coordinating to the 
oxygen atom of the solvent, cerium increases the acidity of the medium and contributes to 
activating the carbonyl of the enone indirectly. These cerium-activated alcohols also react 
with NaBH4 forming a series of alkoxyborohydrides (Scheme 1.31). Since 
alkoxyborohydrides are “hard reagents” they undergo in a selective 1,2-hydride attack on 
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the protonated the cerium complexed carbonyl group of 57 leading to the desired reaction. 
In addition, HCeCl2 may also co-ordinate with the
 C7 hydroxy group, resulting in the 
shielding of the backside of deoxynivalenol.75 As a consequence of this shielding effect, 
the desired front side hydride attack would be more favoured. 
Both the lactones, catenioblin B and Musacin F are having to common allylic alcohol 
moiety, which was generated by the stereoselective and regio-selective organic 
reduction of α,β-unsaturated ketone under Luche conditions (CeCl3.7H2O/NaBH4/MeOH/-
78 oC). 
      
The goal of this Ph.D. work was to develop an efficient, easily accessible synthetic route 
for biologically active natural products especially Catenioblin B and Musacin F lactones. 
These lactones are formed particularly from respective hydroxy acids and the generation of 
chiral hydroxyl centers by different stereoselective methods like asymmetric Sharpless 
epoxidation, Sharpless dihydroxylation and Luches regioselective Syn-reduction etc. After 
obtaining the requisite respective chiral substrate precursors for both Catenioblin B and 
Musacin F were formed via chemoselective oxidative cyclisation under TEMPO/BAIB 
catalytic media and other molecule with an acid catalyzed cyclization was invoked for 
accomplishing the target compounds. 
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2.1 ISOLATION AND STRUCTURE ELUCIDATION OF CATENIOBLIN B 
Many δ-lactone natural products have been found to have a myriad of biological activities, 
including antifungal, antiviral, antioxidative, antibacterial, and antitumor activities 
[pheromones, Paecilosetin, (+)-Asperlin, (+)-Phomalactone and Leodomycin-B etc].1 
However, studies with regard to the insecticidal activities of the natural compounds have 
been rarely reported and discussed. On the basis of chemoecological considerations, our 
group recently embarked on the investigation of entomopathogenic deuteromycetes as a 
source for new bioactive secondary metabolites toward insects and nematodes.2 Since the 
production of secondary metabolites can also be a strategy used by entomopathogenic fungi 
to infect or kill insects, the evaluation and commercial development of natural products 
from these fungi has attracted considerable interest. A preliminary experiment has 
indicated that the ethyl acetate fraction of the fermentation of one fungal strain, 
Paecilomyces cateniobliquus YMF1.01799 leads to the isolation and identification of 
catenioblin B3 by Niu et al., including the isolation of five other metabolites 
[phomalactone, catenioblin A, C, musacin D and cyclo(valyltryptophyl)] and showed 
inhibitory activity toward the growth of cotton bollworms and nematodes. All the 
compounds showed no obvious lethal activities toward the bollworms, since the mean 
corrected mortality rate of Helicoverpa armigera, for all the compounds was not more than 
10% at concentrations of 25−200 μg/mL.  
 
                                                                                                                               Chapter II 
 
38  
 
The structure of 60 (Figure 2.1) was determined on the basis of the 1H NMR and 13C NMR 
spectroscopic data.3 Catenioblin B is a colorless oil, its molecular formula was determined 
to be C8H12O4 by positive HRESI-MS m/z 195.0633 [M + Na]. The UV spectrum showed 
absorption bands λmax (log ε) 281.8 (2.61), 209.6 (3.19) nm, which are consistent with a 
carbonyl group. In addition, the IR spectrum showed the presence of two hydroxyl groups 
(3435 cm-1) and trans di-substituted alkene (1601 cm-1), due to double bond increase single 
bond character of C-O, so lower force constant leads to lower frequency. Inspection of the 
1H and 13C NMR spectral data revealed the presence of one methyl [δH 1.69 (3H, d, J = 6.2 
Hz), δC 17.9 ], two methylene protons are H-2a [δH 2.75 (1H, dd, J = 17.4, 6.8 Hz), H-2b 
δH 2.57 (1H, dd, J = 17.4, 2.3 Hz) and δC 39.2 (t)], olefinic protons H-6 coupled with the 
adjacent other olefinic H-7 as well as coupled with oxygenated methane split into ddd [δH 
5.61 (1H, ddd, J = 15.3, 6.8 and 1.0 Hz),  5.85 (1H, m) and δC 128.1, 131.0] and three 
oxygenated methanes are H-3 [δH 4.60 (m), H-4 [δH 4.30 (1H, t, J = 4.1)] and H-5 [δH 4.51 
(1H, dd, J =  6.8, 4.1)] and  δC doublets at 69.1, 84.7, 71.6. Due to off-resonance 
decoupling of the one bond C-H couplings are retained and so the signal for a particular C 
is given by the number of attached H’s in according with the n+1 rule. Based on the above 
data the structure of 60 confirmed as shown in Figure 2.1 as catenioblin B. 
2.2 Present work 
         Catenioblin B 60 has a fascinating biological profile, apart from that it structurally 
belongs to the polyol containing chiral δ-lactones4 that have attracted much attention due to 
their importance as building blocks in natural product synthesis.5 For instance, the presence 
of a cis vicinal diol at the C3-C4 positions and trans double bond makes this molecule 
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synthetically interesting (Figure 2.1). The total synthesis of catenioblin B 60 is described in 
this chapter.  
2.3 Retrosynthetic strategy 
 
The retrosynthetic analysis of catenioblin B 60 is illustrated in Scheme 2.1. Our approach is 
mainly through the regio-selective epoxide ring-opening reaction6 of known epoxy alcohol 
627 towards accessing the polyol system in the critical intermediate 71. The chiral alcohol 
intermediate 71 could be conceivably obtained from the alcohol derivative 63 via a 
sequence of transformations followed by oxidation and Grignard reaction, a key step in the 
synthesis of the chiral allyl alcohol 71 would arise by the Luche reduction, followed by 
deprotection of the PMB-ether and pyranose ring cyclization under TEMPO/BAIB 
conditions and finally cis-diol deprotection would furnish the natural product 60.  
2.4 Results and Discussions 
        Accordingly, the advanced intermediate 71 (Scheme 2.1) was accessed from the 
allylic alcohol 61 that was made from 1,3-propane diol according to a reported 
procedure.6b,c Consequently, epoxidation of the allyl alcohol 61 (Scheme 2.2) by the 
Sharpless condition7 {(+)- DIPT/Ti(OiPr)4/TBHP/CH2Cl2/-20 
oC} gave epoxy alcohol 62 in 
83% yield with >95% ee. Formation of epoxide 62 was confirmed from 1H NMR spectral 
analysis wherein the protons attached to the epoxide ring resonated at δ 3.09 and δ 2.97 
ppm as a multiplet. The disappearance of olefinic protons further substantiated the 
formation of the epoxide. The remaining protons resonated at the expected chemical shifts. 
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Next, the desired chiral anti-diol functionality was introduced by using the Sharpless 
protocol (Scheme 2.3). A Lewis acid Ti(OiPr)4 promoted regioselective 2,3-epoxide ring-
opening reaction6 of chiral epoxy alcohol 62 with benzoic acid furnished the dihydroxy 
benzoate derivative 63 as the sole product favouring an exclusive C3-attack in good yield 
85% (no trace of the other isomer was detected in the 1H NMR spectrum). The 1H NMR 
spectrum of 63 displays the presence of 9 aromatic protons, 5 from benzoyl and 4 from the 
p-methoxybenzyl, a CH-OBz proton at δ 5.21 ppm as doublet of triplet, the CH2 protons of 
the PMBO are diasterotopic and appear as geminal coupled doublets at δ 4.4 ppm. The rest 
of the protons resonating at characteristic chemical shifts showing the formation of the 
required product 63. The relative stereochemistry at C2 and C3 was determined as anti 
based on our previous reports.6 Thus, the absolute stereochemistry at both chiral centres 
was assigned at C2 as ‘R’ and at C3 as ‘S’. This explains the titanium(IV)-mediated regio- 
and stereoselective C3 epoxide ring-opening reaction of chiral epoxy allyl alcohol 62 with 
benzoic acid (Nu-) by the formation of highly-substituted chelate complex with Ti(OiPr)4 
into a polyol 63. Incidentally, it may be recalled that C2-OH in 63 correlates to the C3 
stereogenic centre and C3-OH to C4 stereogenic centre in the natural product. And also the 
anti-stereochemistry of the diol was determined after it was converted into an 
isopropylidene derivative (Scheme 2.6). IR spectrum showed absorption peaks at 3395, 
3011 (O-H), 1712 (C=O) and 1068 (C-O) cm-1. The dihydroxy benzoate structure of 63 
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was supported by the HRMS: m/z [M+Na]+ calcd. C20H24O6 Na [M+Na]
+: 383.1465; 
found: 383.1466. 
 
Then the TBS group was selectively installed at the primary hydroxyl group of 63 under 
standard conditions by treatment with TBSCl in the presence of imidazole and a catalytic 
amount of Bu2SnO in CH2Cl2 at 0 
oC to room temperature to afford the corresponding 
TBS-ether product 64 in 90% yield (Scheme 2.4). The selective formation of mono silyl 
derivative was achieved by the use of catalytic amounts of Bu2SnO (Scheme 2.4) to form 
the corresponding stannyl ester followed by its regio-selective opening. This can be 
explained by chelation of tin oxide with the 1,2-diol to form the tin-acetal intermediate 63a. 
Such an intermediate directs the silyl group from the less hindered side and reduces the 
reaction time drastically due to activation of the diol for direct approach. The stannylene 
acetal intermediate 63a shown in scheme 2.4 accomplishes primary hydroxyl activation 
and temporary secondary hydroxyl protection in a single operation. The 1H NMR spectrum 
of 64 showed the methyl protons of tert-butyl resonate at δ 0.88 ppm and the Si(CH3)2 
protons at δ 0.04 ppm as singlet indicative of the presence of TBS group. The structure was 
further supported by HRMS: m/z [M+Na]+ calcd. 497.2329, found 497.2327 for 
C26H38O6NaSi. 
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Hydrolysis of the benzoate 64 under basic conditions occurred by treatment with K2CO3 
and MeOH at room temperature for 3 h gave the anti-diol 65 in 85% yield (Scheme 2.5). It 
was confirmed by the analytical data. The 1H NMR spectral analysis of 65 revealed the 
disappearance of aromatic peaks corresponding to benzoyl group while the rest of the 
protons resonated at their expected chemical shifts. This was also supported by HRMS: m/z 
calcd for C19H34O5SiNa [M+Na]
+: 393.2067; found: 393.2068. 
 
The diol 65, was then masked as the acetonide by reaction with 2,2-dimethoxy propane and 
PPTS (cat.) in CH2Cl2 for 3 h to furnish the acetonide derivative 66 in 80% yield (Scheme 
2.6). In the 1H NMR spectrum the acetonide protons resonated at δ 1.41 ppm and δ 1.33 
ppm as two singlets, while rest of the protons resonated at the expected chemical shifts 
supporting the formation of the product 66. Further structural confirmation was obtained by 
observing the 13C NMR signals for the geminal dimethyl groups of the isopropylidene ring 
of compound 66 that appeared at δ 28.2 and 25.8 ppm and were in agreement with the non-
equivalence of the gem-dimethyl groups for a 1,2-anti-diol system as previously reported.8 
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The molecular structure was also supported by HRMS: m/z calcd for C22H42O5NSi 
[M+NH4]
+: 428.2827; found: 428.2825. 
 
Desilylation of 66 with TBAF (1.0 M in THF) in THF at 0 ºC to rt for 3 h afforded the 
isopropylidene derivative 67 in 86% yield (Scheme 2.7). This was characterized by the 1H 
NMR spectrum where the resonances due to the TBS group at δ 0.88 ppm and δ 0.05 ppm 
were absent, while the rest of the protons appeared at their expected chemical shifts. The 
IR spectrum showed the stretching frequency of C-H bond at 3009 cm-1 supporting the 
presence of a primary hydroxyl group. Further the structure of 67 was supported by 
HRMS: m/z calcd for C16H24O5Na [M+Na]
+: 319.1516; found: 319.1514. 
 
Then, (Scheme 2.8) the primary alcohol 67 was subjected to a Swern oxidation followed by 
a Grignard reaction9 (1-propenyl magnesium bromide/THF/0 oC) to afford allyl alcohol 68 
as a syn/anti diastereomeric mixture along with its E,Z-isomers with 82% yield (over two 
steps). The separation of each of the syn/anti along with the E,Z-isomers was difficult, due 
to very close proximity on TLC. We decided to obtain the desired isomer from the mixture 
without separation after the oxidation. Thus, it was subjected to Dess-Martin periodinane 
(DMP) oxidation to provide the α,β-unsaturated ketone as a separable (3:2) E/Z mixture 
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69a, 69b yielded 92%. The diastereomeric ratio was determined from the isolated yield. 
This mixture separated on TLC plate and the E, Z-isomers were separated by column 
chromatography and the E-isomer was used in the next step. The E-isomer 69a was 
isolated 90% from the mixture and the overall yield after isolation was 53% and the major 
isomer was confirmed by the 1H NMR, which revealed the presence of olefinic protons at δ 
6.93-7.05 ppm as a multiplet and δ 6.5 as a doublet of doublet (J = 15.6, 1.7Hz) each 
integrating for one proton confirming the formation of the trans geometry of the olefin in 
the oxidation product. The 13C NMR spectrum of the carbonyl carbon resonated at δ 197.2. 
The IR spectrum showed the stretching frequency of α,β- unsaturated C=O bond at 1690 
cm-1 as the confirmation of ketone group. HRMS: m/z calcd for C19H26O5Na [M+Na]
+: 
357.1615; found: 357.1613.  
 
The purified E-isomer 69a was reduced under Luche reduction conditions10 (CeCl3. 
7H2O/NaBH4/MeOH/-78 
oC) to afford the chiral allylic alcohol 70 (Scheme 2.9) in 90% 
yield. The absolute stereochemistry at C5 was tentatively assigned as ‘S’ based on previous 
literature evidence,11 i.e when the cerium salts are mixed with NaBH4, the role of cerium is 
twofold, it contributes catalysis of the formation of alkoxyborohydrides, and also increases 
the electrophilicity of the carbonyl carbon atom by co-ordinating of the oxygen atom to 
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cerium, (increases the acidity of the medium) this contributes to activating the carbonyl of 
the enone indirectly. These cerium-activated alcohols also react with NaBH4 forming a 
series of alkoxyborohydrides. Since alkoxyborohydrides are “hard reagents” they undergo 
in a selective 1,2-hydride attack on the protonated carbonyl group of 69a leading to the 
desired reaction. In addition, the CeCl3 also reacts with NaBH4 to form HCeCl2, it may co-
ordinate with the C4 hydroxy group of 69a intermediate, resulting in the shielding of the 
front side. As a consequence of this shielding effect, the desired back side hydride attack is 
more favourable for the formation of hydroxyl group of 70 in syn orientation (C4-C5) with 
each other that may result in the formation of the major S-alcohol11 and that was 
subsequently confirmed by extensive NMR as well as LCMS studies. The 1H NMR 
spectrum of 70 revealed the appearance of one peak δ 3.96 proton resonating as an 
apparent triplet or described as a doublet of doublet. The de of allylic alcohol 70 was 
calculated as 93.4% by LCMS {column: XCB C18 column, 30% water (NH4OAc 10 mm) 
in acetonitrile, flow rate: 1 mL/min, 254 nm, tr(major) = 9.555 min, tr(minor) = 8.843 min} 
in favor of S-alcohol (major).  HRMS: m/z calcd for C19H28O5Na [M+Na]
+: 359.1816; 
found: 359.1814. 
 
The deprotection of the allylic alcohol 70 under mild oxidizing conditions, using DDQ 
(Scheme 2.10) led to the crucial primary alcohol 71 in an 88% yield. Diol 71 was 
confirmed by the 1H NMR spectrum that revealed the disappearance of aromatic peaks 
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corresponding to the 4-methoxy benzoyl group while the rest of the protons resonated at 
characteristic chemical shifts. It was also supported by HRMS: m/z calcd for C11H20O4Na 
[M+Na]+: 239.1253; found: 239.1250. 
 
The assignments of the stereochemistry at C5 centre of compound 71 were based on the 
1H-1H COSY and NOESY experiments that revealed the absence of NOE between 
C5H/C3H that suggested that both protons are in trans orientation to each other and with 
opposite facial orientation. This was supported by the NOE correlation between C3H/CH1, 
C3H/Me-A, C5H/Me-B, C5H/C7H and C6H/C8H (Figure 2.2a). Which is supported by 
showing the energy minimized diagram (Figure 2,2b). 
                                                
Figure 2.2a: NOE correlations               Figure 2.2b: Energy minimized structure                      
Then the primary alcohol 71 was subjected to TEMPO/BAIB oxidation conditions12 
(Scheme 2.11) to afford the cyclized product 72 yielded 88%. The lactone 72 was 
completely characterized. 1H NMR that showed that disappearance of the OCH2 protons as 
it was transformed into the carbonyl functional group during oxidation and disappearance 
of methylene protons adjacent to the carboxyl carbon that appeared at  2.5-2.80 ppm as a 
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multiplet. The 13C NMR showed that signal a corresponding to carbonyl carbon appeared at 
 171.7 ppm. IR spectrum showed absorption peak at 1725 (C=O) cm-1. Further it was 
supported by HRMS: m/z calcd for C11H16O4Na [M+Na]
+: 235.09408 ; found: 235.09475. 
 
Finally, the cyclized product 72 upon deprotection of the acetonoide group under acidic 
conditions with Amberlyst-1513 led to the final target 60 (Scheme 2.12) in a yield of 78%. 
The 1H NMR spectrum of 60 revealed the absence of the two methyl group proton peaks 
corresponding to the acetonide group. The IR spectrum showed an absorption peak for the 
ester at 1725 (O-C=O) cm-1. Further it was supported by HRMS: m/z calcd for C8H12O4Na 
[M+Na]+: 195.06278; found: 195.06205.  
 
Similarly compound 60, being a cyclic structure also showed (Figure 2.3a) the NOE 
correlations between C3H/C5H, C5H/C7H and C6H/C8H, one of the evidence to that the 
chiral centre C5 assigned as ‘S’ was indeed correct which is supported by the lowest energy 
structure in  Figure 2.3a, b.  
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Figure 2.3a: NOE correlations for 60              Figure 2.3b: Energy minimized structure 60 
In order to rationalize the differences in optical rotation values between the synthetic 60 
and with the natural product, it was decided to record the same at different concentrations 
for the synthetic. The reported optical rotation of the natural product value []
25
D  = -2.72 (c 
0.16, MeOH) given for 60 could not be repeated, since no specific rotation was detected at 
c 0.16, (MeOH). However, it was measured as []
25
D  = -6.83 (c 1.5, MeOH) and []
25
D  = -
6.95 (c 0.7, MeOH).  Since the reported value []
25
D  = -2.72 (c 0.16, MeOH) is very low, 
the difference in optical rotation values between the two might be explained by an error in 
concentration and temperature. 
2.5 Conclusion 
      The synthetic route was developed for the target molecule i.e catenioblin B 60 was in 
12 with 7.7% over all yield, featuring the titanium (IV) mediated regioselective epoxide 
ring-opening reaction of the known epoxy alcohol 62 and stetroselective Luche reduction 
as the synthetic tool to achieve the critical intermediate 71 with three chiral centres. 
Finally, pyranone ring cyclization under TEMPO/BAIB conditions and cis-diol 
deprotection furnished the natural product 60. However, the limitations of this catenioblin 
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B synthesis are the extensive use of protecting groups. This synthesis strategy could be 
adopted for the synthesis of these types of metabolite related natural products. 
GENERAL REMARKS 
 
1. Nuclear Magnetic Resonance spectra were recorded on Varian FT-200 MHz 
(Gemini), AVANCE-300 MHz (Bruker), Varian VXR Unity-400 MHz and 500 
MHz spectrometers using tetramethylsilane (TMS) as the internal standard. 
Chemical shifts have been expressed in () ppm units downfield from TMS. 
Selected data are reported as follows. Chemical shifts, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, qt = quintet, m = multiplet, br = broadened, dd = 
doublet by doublet, dt = doublet by triplet and td = triplet by doublet), coupling 
constants (J in Hz) and assignments. 
2. Mass spectra were recorded on CEC-21-11013 or Finningan Mat 1210 double 
focusing mass spectrometers operating at 70 eV using a direct inlet system. 
3. FABMS and HRMS were measured using VG AUTOSPEC mass spectrometers at 
5 or 7 K resolution using perfluorokerosene as an internal reference compound. 
4. Optical rotations were measured with a Jasco Dip 300 digital polarimeter at 25 °C. 
5. Melting points were recorded on Büchi 535 melting point apparatus and are 
uncorrected. 
6. All evaporations were carried out under reduced pressure on a Büchi rotary 
evaporator below 40 °C. 
7. All solvents and reagents were purified and dried by standard techniques. 
8. All the reactions monitored by analytical thin layer chromatography (TLC) using E-
Merck silicagel plates (60G-254). Visualization was accomplished with UV light 
(256 mm), iodine and by dipping in 2% phosphomolybdic acid in 15% aq. H2SO4 or 
2.75% p-anisaldehyde in 3% H2SO4 or -naphthol in 5% H2SO4 in EtOH or 
Ninhydrin in Methanol and acetic acid followed by heating. 
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9. All non-aqueous reactions were carried out under nitrogen (N2) atmosphere using 
dry, freshly distilled solvents unless otherwise noted. Yields refer to 
chromatographic and spectroscopic homogeneous isolated materials unless 
otherwise stated. 
10. Nomenclature mentioned in the experimental section was adopted from ACD/ 
Name version 1.0 , Advanced Chemistry Development Inc., Toronto, Canada. 
11. Room temperature = 25-27 °C. 
12. Petroleum ether boiling point is 65-70 °C. 
13. ‘Brine’ means saturated aqueous NaCl solution. 
14. 60-120 Mesh silica gel is generally denoted as ‘Silica gel’ (acme’s Laboratory 
Chemicals for Chromatography). 
 
 
 
 
 
 
 
 
 
                                                                                                                               Chapter II 
 
51  
 
2.6 Experimental procedures 
2.6.1 ((2R,3R)-3-(2-((4-Methoxybenzyl)oxy)ethyl)oxiran-2-yl)methanol (62) 
 
To a stirred solution (Scheme 2.2) of (–)-DIPT (0.62 g, 2.6 mmol) in CH2Cl2 (20 mL) 
containing 4 Å molecular sieves (0.5 g), was sequentially added Ti(Oi-Pr)4 (0.4 mL, 1.3 
mmol), and tert-Butyl hydroperoxide in CH2Cl2 (5M) (4 mL, 20.0 mmol) at -20 oC and the 
reaction mixture stirred for 20 min; to this a solution of allyl alcohol 61 (3 g, 13.3 mmol) in 
CH2Cl2 (15 mL) was added at the same temperature and the stirring continued for 12 h at 
the same temperature to complete the reaction (monitored by TLC). The reaction was then 
quenched with 10% NaOH solution (1.5 g in 15 mL brine, 3 mL), stirred for 2 h, and 
filtered. The organic layer from the filtrate was dried over anhydrous Na2SO4 and 
evaporated to dryness under reduced pressure. The residue was purified by column 
chromatography (Silica gel 60-120 mesh, EtOAc: n-hexane, 30:70) to furnish epoxy 
alcohol 62 (2.62 g, 83%, >95% ee)7 as a colorless oil. []
25
D  = +18.7 (c 1.2, CHCl3); 
1H 
NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 4.45 (s, 2H), 
3.91 (dd, J = 2.5, 12.5 Hz, 1H), 3.81 (s, 3H), 3.62 (dd, J = 4.3, 12.5 Hz, 1H), 3.58 (t, J = 
6.6 Hz, 2H), 3.10 (ddd, J = 2.5, 4.3, 6.3 Hz, 1H), 2.97 (td, J = 2.5, 4.3 Hz, 1H), 1.75-1.99 
(m, 2H,); 13C NMR (75 MHz, CDCl3) δ 159.2, 129.3, 113.9, 72.9, 66.7, 61.8, 58.5, 55.5, 
53.9, 32.3.; HRMS: m/z calcd for C13H18O4Na (M+Na)
+: 261.1103, found: 261.1105. 
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2.6.2 (2R,3S)-1,2-Dihydroxy-5-((4-methoxybenzyl)oxy)pentan-3-yl benzoate (63)  
 
To a stirred solution (Scheme 2.3) of epoxy alcohol7 62 (2 g, 8.4 mmol) in dry CH2Cl2 (20 
mL) was added Ti(OiPr)4 (3.70 mL, 12.6 mmol) under dry and inert atmosphere. The 
mixture was stirred for 15 min, benzoic acid (2.05 g, 16.8 mmol) was added, and the 
mixture was allowed to warm up to room temperature and stirred for 3 h. The CH2Cl2 was 
evaporated under reduced pressure, the mixture was diluted with diethyl ether (20 mL), and 
3% H2SO4 (10 mL) was added, and the mixture was allowed to stir until two clear layers 
were obtained (1 h). The two layers were separated. The organic layer was washed with a 
saturated aq.solution of NaHCO3 (20 mL) and, brine (20 mL) dried (Na2SO4), and 
concentrated in vacuo. The residue was purified by column chromatography (Silica gel 60-
120 mesh, EtOAc: n-hexane, 50:50) to yield dihydroxy benzoate 63 (2.57 g, 85%) as pale 
yellow liquid. []
25
D  = -3.0 (c 1.5, CHCl3);
 1H NMR (300 MHz, CDCl3): δ 8.03-7.95 (m, 
2H), 7.62-7.53 (m, 1H), 7.43 (t, J = 7.5 Hz, 2H), 7.21 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.6 
Hz, 2H), 5.21 (ddd, J = 6.7, 4.1 Hz, 1H), 4.43 (d, J = 3.3 Hz, 2H), 3.86-3.78 (m, 1H), 3.76 
(s, 3H), 3.75-3.50 (m, 4H), 2.26-2.01 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 166.4, 
159.2, 133.2, 129.5, 128.3, 113.7, 72.9, 72.6, 72.3, 65.6, 62.9, 55.1, 31.0; HRMS: m/z calcd 
for C20H24O6 Na [M+Na]
+: 383.1465; found: 383.1466. 
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2.6.3 (2R,3S)-1-((tert-Butyldimethylsilyl)oxy)-2-hydroxy-5-((4-methoxybenzyl)oxy) 
pentan-3-yl benzoate (64)  
 
To a stirred solution of (Scheme 2.4) dihydroxy benzoate 63 (2.4 g, 6.66 mmol) in dry 
CH2Cl2 (30 mL) at 0 ºC dibutyl tin oxide (cat) was added and stirred for it 10 min then 
imidazole (0.90 g, 13.33 mmol) was added at the same temperature and stirred for about 30 
min, then tert-butyldimethyl silylchloride (1.02 g, 6.8 mmol) was added and stirred for 3 h. 
The reaction mixture was diluted with CH2Cl2 (15 mL) and washed with water (20 mL), 
and brine (15 mL), dried (Na2SO4) and concentrated in vacuo. The crude residue purified 
by column chromatography (Silica gel 60-120 mesh, EtOAc:n-hexane, 20:80) to afford 64 
(2.84 g, 90%) as a pale yellow liquid. []
25
D  = +5.3 (c 0.7, CHCl3);
  1H NMR (500 MHz, 
CDCl3): δ 8.00 (d, J = 7.4 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.4 Hz, 2H), 7.20 
(d, J = 8.6 Hz, 2H), 6.80 (d, J = 8.6 Hz, 2H), 5.34-5.26 (m, 1H), 4.41 (br. s, 2H), 3.93-3.85 
(m, 1H), 3.77 (s, 3H), 3.73 (dd, J = 3.9, 6.2 Hz, 1H), 3.68-3.52 ( m, 3H), 2.99 (d, J = 5.0 
Hz 1H), 2.20-2.07 (m, 2H), 0.88 (s, 9H), 0.04 (s, 6H); 13C NMR (75 MHz, CDCl3): δ 
165.9, 159.1, 132.9, 130.2, 129.4, 128.3, 113.7, 72.7(2), 72.4, 66.0, 63.7, 55.2, 30.4, 25.8, 
18.2, -5.4(2); HRMS: m/z calcd for C26H38O6NaSi [M+Na]
+: 497.2329; found: 497.2328. 
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2.6.4 (2R,3S)-1-((tert-Butyldimethylsilyl)oxy)-5-((4-methoxybenzyl)oxy)pentane-2,3-
diol (65) 
 
To stirred solution (Scheme 2.5) of 64 (2.7 g, 5.69 mmol) in MeOH (30 mL) was added 
solid potassium carbonate (1.17 g, 8.54 mmol) at 0 oC and allowed it to stir at room 
temperature. After stirring for 3 h, solvent MeOH was removed under reduced pressure. 
The crude residue was washed with water (15 mL) and extracted with EtOAc (2 x 20 mL). 
The organic layer was dried (Na2SO4), concentrated and purified by column 
chromatography (Silica gel 60-120) mesh, EtOAc:n-hexane 30:70) to obtain diol 65 (1.79 
g, 85%) as a pale yellow liquid. []
25
D  = +11.0 (c 1.8, CHCl3); 
1H NMR (300 MHz, 
CDCl3): δ 7.25 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.46 (s, 2H), 3.80 (s, 1H), 
3.79-3.63 (m, 4H), 3.58-3.37 (m, 2H), 2.89 (br.s, 1H), 2.04-1.72 (m, 2H), 0.90 (s, 9H), 0.09 
(s, 6H); 13C NMR (125 MHz, CDCl3): δ 159.2, 129.8, 129.3, 113.8, 73.2, 73.0, 72.5, 68.4, 
64.4, 55.2, 32.5, 25.8, 18.2, -5.4(2); HRMS: m/z calcd for C19H34O5SiNa [M+Na]
+: 
393.2067; found: 393.2068. 
2.6.5 tert-Butyl(((4R,5S)-5-(2-((4-methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-
4-yl)methoxy)dimethylsilane (66)  
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To a stirred solution of (Scheme 2.6) diol 65 (1.7 g, 4.59 mmol) in dry CH2Cl2 (10 mL) at 0 
°C PPTS (cat.) was added and the solution stirred for 20 min, and then 2,2-DMP (1.12 mL, 
9.13 mmol) was added and the solution stirred for additional 3 h. The reaction mixture was 
quenched with Et3N (0.5 mL) and concentrated in vacuo. The crude residue was purified by 
column chromatography (Silica gel 60-120 mesh, EtOAc:n-hexane, 10:90) to afford 66 (1.5 
g, 80%) as a colorless liquid. []
25
D  = -11.3 (c 0.9, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 
7.26 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.45 (br. s, 2H), 4.35-4.29 (m, 1H), 4.11-
4.04 (m, 1H), 3.80 (s, 3H), 3.69-3.56 (m, 4H), 2.00-1.77 (m, 2H), 1.41 (s, 3H), 1.33 (s, 
3H), 0.88 (s, 9H), 0.05 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 159.1, 130.6, 129.1, 113.7, 
107.7, 77.7, 74.3, 72.6, 67.2, 62.0, 55.2, 29.5, 28.2, 25.8, 25.5, 18.2, -5.4, -5.3; HRMS: m/z 
calcd for C22H42O5NSi [M+NH4]
+: 428.2827; found: 428.2825. 
2.6.6 ((4R,5S)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)methanol (67)  
 
To a stirred solution of (Scheme 2.7) compound 66 (1.4 g, 3.41 mmol) in anhydrous THF 
was added 5 mL of TBAF (1.33 g, 5.12 mmol, 1.0 M solution in THF) at 0 oC and reaction 
mixture stirred at room temperature for 2 h then the solvent was concentrated in vacuo. The 
crude residue was purified by column chromatography (Silica gel 60-120 mesh, EtOAc:n-
hexane, 22:78) to afforded primary alcohol 67 (0.86 g , 86%) as a pale yellow oil. []
25
D  = 
+1.9 (c 1.6, CHCl3); 
1H NMR (500 MHz, CDCl3): δ 7.25 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 
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8.6 Hz, 2H), 4.45 (s, 2H), 4.33-4.27 (m, 1H), 4.19-4.12 (m, 1H), 3.80 (s, 3H), 3.67-3.54 (m, 
4H), 2.38-2.21 (br. s, 1H), 1.94-1.81 (m, 2H), 1.45 (s, 3H), 1.36 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 159.2, 130.0, 129.3, 113.7, 107.8, 77.8, 74.6, 72.8, 67.0, 61.6, 55.2, 29.3, 
28.1, 25.4; HRMS: m/z calcd for C16H24O5Na [M+Na]
+: 319.1516; found: 319.1514. 
2.6.7 1-((4R,5S)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)but-2-en-1-ol (68) 
 
To a solution of (Scheme 2.8) oxalyl chloride (0.44 mL, 4.78 mmol) in dry CH2Cl2 (5 mL) 
at -78 0C, dry DMSO (0.73 mL, 9.57 mmol) was added dropwise and stirred for 10 min. A 
solution of primary alcohol 67 (0.77 g, 2.60 mmol) in dry CH2Cl2 (2 mL) was added and 
stirred for 1 h at -78 OC. It was quenched with Et3N (2.6 mL, 19.15 mmol) and diluted with 
CH2Cl2 (20 mL). The reaction mixture was washed with water (10 mL), brine (5 mL), dried 
(Na2SO4) and evaporated to furnish the corresponding aldehyde.  
To a stirred solution of aldehyde (0.66 g, 2.24 mmol) in THF (6 mL), 1-propenyl 
magnesium bromide (0.65 mL, 4.4 mmol) was added at 0 ºC. Then sat. aq. NH4Cl (3 mL) 
was added slowly and stirred for 2 h. Later, quenched with aq. sat. NH4Cl (10 mL), 
extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine 
(20 mL), dried (Na2SO4) and concentrated in vacuo. The crude residue was partially 
purified by column chromatography (Silica gel 60-120 mesh, EtOAc:n-hexane, 25:75) to 
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afford 68 as an inseparable syn/anti mixture along with E,Z- isomers (0.615 g, 82%). 
Spectral analysis was difficult due to the diastereomeric mixture of products. 
2.6.8 (E)-1-((4S,5S)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)but-2-en-1-one (69a)  
 
To a stirred solution of (Scheme 2.9) alcohol 68 (0.56 g, 1.66 mmol) in anhydrous CH2Cl2 
(5 mL) under N2 atmosphere at 0 
oC Dess-Martin Periodinane (1.06 g, 2.5 mmol) was 
added and reaction mixture stirred at room temperature for 2 h. After that quenched with 
1:1 mixture of aq. sat. solution of Na2S2O3 and NaHCO3 (5 mL), then extracted with 
CH2Cl2 (2 x 20 mL), the combined organic layer was washed with water (20 mL), brine (20 
mL), dried over (Na2SO4), concentrated and the crude residue was formed as E/Z separable 
mixture 69a, 69b 92% yield in 3:2 ratio, was purified by column chromatography (Silica 
gel, 60-120 mesh, EtOAc:n-hexane, 25:75) to separate a E-isomer 69a (0.29 g, 53% overall 
yield) as a yellow oil. []
25
D  = -14.23 (c 1.2, CHCl3);
  1H NMR (300 MHz, CDCl3): δ 7.24 
(d, J = 8.6 Hz, 2H), 6.93−7.05 (m, 1H), δ 6.87 (d, J = 8.6 Hz, 2H), 6.5 (dd, J = 1.7, 15.6 
Hz, 1H), 4.52-4.62 (m, 2H), 4.42 (s, 2H), 3.80 (s, 3H), 3.55 (q, J = 5.2, 7.3 Hz, 2H), 1.91 
(dd, J = 1.7, 6.9 Hz, 3H), 1.66-1.77, (m, 2H), 1.61 (s, 3H), 1.39 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 197.2, 159.1, 144.5, 130.4, 127.5, 113.6, 109.9, 81.7, 74.9, 72.6, 66.6, 
55.2, 30.9, 27.1, 25.0, 18.5; HRMS: m/z calcd for C19H26O5Na [M+Na]
+: 357.1615; found: 
357.1613. 
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2.6.9 (S,E)-1-((4R,5S)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4 
yl)but-2-en-1-ol (70)  
 
To a stirred solution of (Scheme 2.10) γ,β-unsaturated ketone 69a (0.2 g, 0.59 mmol) and 
CeCl3·7H2O (0.05 g, 0.15 mmol) were dissolved in MeOH (2 mL) and cooled to 0 °C. 
NaBH4 (0.022 g, 0.59 mmol) was dissolved in MeOH (0.5 mL) and added within 5 mins to 
the reaction solution via a dropping funnel. After complete addition of the NaBH4 solution 
the cooling bath was removed and the reaction continued. TLC (n-hexane:EtOAc = 70:30) 
after 4 h revealed consumption of the starting material and the reaction was treated with 2N 
HCl (5 mL) and extracted with Et2O (3 x 10 mL). The organic phase was dried over 
Na2SO4, filtered and the solvent was removed under reduced pressure. Column 
chromatography (Silica gel, n-hexane:EtOAc, 70:30) yielded 70 (0.178 g, 90%) as a 
slightly yellow oil.  []
25
D  = -8.3 (c 0.5, CHCl3);
 1H NMR (300 MHz, CDCl3): δ 7.26 (d, J = 
8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 5.71-5.84 (m, 1H), 5.45 (ddd, J = 1.5, 7.1, 15.4 Hz, 
1H), 4.4 (s, 2H), 4.30 (q, J = 6.0 Hz, 1H), 4.09 (br. s, 1H), 3.96 (t, J = 6.0 Hz, 1H), 3.81 (s, 
3H), 3.55-3.61 (m,  2H), 2.35 (br. s, 1H), 1.85-1.90 (m, 2H), δ 1.71 (d, J = 6.4 Hz, 3H), 
1.49 (s, 3H), 1.37 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 159.1, 129.8, 129.2, 113.7, 
107.9, 80.2, 74.2 , 72.7, 70.7, 67.1, 55.2, 30.2, 25.3, 27.7, 17.9,; HRMS: m/z calcd for 
C19H28O5Na [M+Na]
+: 359.1816; found: 359.1814. 
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2.6.10 (S,E)-1-((4R,5S)-5-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)but-2-en-1-
ol (71)  
 
To a stirred solution of (Scheme 2.11) PMB ether 70 (0.15 g, 0.44 mmol) in CH2Cl2:H2O 
(19:1) (2 mL) was added DDQ (0.13 g, 0.58 mmol) at 0 oC and reaction mixture stirred at 
room temperature for 1 h. Then aq. sat. NaHCO3 (0.5 mL) was added and extracted with 
CH2Cl2 (10 mL), the combined organic layer was washed with water (5 mL), brine (5 mL), 
dried over (Na2SO4), concentrated and the crude residue was purified by column 
chromatography (Silica gel, 60-120, EtOAc:n-hexane, 43:57) to afford a primary alcohol 
71 (0.083 g, 88%) as yellow oil. []
25
D  = -12.9 (c 0.5, CHCl3);
 1H NMR (300 MHz, CDCl3): 
5.77-5.90 (m, 1H), 5.46 (ddd, J = 1.5, 6.7, 15.1 Hz, 1H), 4.29-4.36 (m, 1H), 4.11 (t, J = 6.7 
Hz, 1H), 4.01 (t, J = 6.0 Hz, 1H), 3.80-385 (m,  2H), 2.37 (br. s, 1H), 1.86-1.99 (m, 2H), δ 
1.73 (d, J = 6.0 Hz, 3H), 1.52 (s, 3H), 1.38 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 130.3, 
129.5, 108.4, 80.4, 76.1, 70.7, 61.1, 32.1, 27.8, 25.4, 17.9,; HRMS: m/z calcd for 
C11H20O4Na [M+Na]
+: 239.1253; found: 239.1250. 
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2.6.11 (3aS,4S,7aS)-2,2-Dimethyl-4-((E)-prop-1-en-1-yl)tetrahydro-6H-
[1,3]dioxolo[4,5-c]pyran-6-one (72)  
 
To a stirred solution (Scheme 2.12) of diol 71 (0.05 g, 0.23 mmol) in CH2Cl2:H2O (1:1, 1 
mL) was added TEMPO (cat.) and BIAB (0.22 g, 0.68 mmol) successively at 0 oC and 
allowed to stir at room temperature for 6 h. Later, the reaction mixture was quenched with 
sat. aq. Na2S2O3 (0.5 mL) and extracted with CH2Cl2 (2 x 5 mL). The combined organic 
layers were washed with water (3 mL), brine (5 mL), dried (Na2SO4) and evaporated. The 
residue was purified by column chromatography (Silica gel, 60-120 mesh, EtOAc:n-
hexane, 25:75) to give lactone 72 (0.042 g, 88%) as a pale yellow liquid. []
25
D  = -12.43 (c 
1.8, CHCl3);
 1H NMR (300 MHz, CDCl3): 5.87-5.93 (m, 1H), 5.72 (ddd, J = 1.6, 7.7, 15.5 
Hz, 1H), 4.70-4.73 (m, 1H), 4.48 (d, J = 7.7 Hz, 1H), 4.38 (dd, J = 1.8,  7.6 Hz, 1H), 2.88 
(dd, J = 2.3, 15.8 Hz, 1H), 2.52 (dd, J = 3.6, 15.8 Hz, 1H), 1.78 (dd, J = 1.5, 6.4 Hz, 3H), 
1.47 (s, 3H), 1.34 (s, 3H),; 13C NMR (75 MHz, CDCl3): δ 171.7, 132.1, 124.2, 109.4, 78.9, 
74.7, 71.4, 34.5, 25.9, 24.1, 17.8,; HRMS: m/z calcd for C11H16O4Na [M+Na]
+: 235.09408 ; 
found: 235.09475. 
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2.6.12 (4S,5S,6S)-4,5-Dihydroxy-6-((E)-prop-1-en-1-yl)tetrahydro-2H-pyran-2-one 
(60) 
 
To the stirred solution (Scheme 2.13) of 72 (0.02 g, 0.09 mmol) in CH2Cl2 was added 
Amberlyst® 15 at room temperature under neat condition allowed to stir for 4 h. Then the 
reaction mixture was filtered through a celite pad with EtOAc (10 mL), the celite pad was 
further washed with the EtOAc (2x5 mL) the combined organic layers was washed with 
water (5 mL), brine (6 mL), and dried over (Na2SO4), concentrated and the crude residue 
was purified by column chromatography (Silica gel, 60-120 mesh, EtOAc:n-hexane, 50:50) 
to afford final target 60 (0.012 g, 78%) as a yellow oil. []
25
D  = -6.83 (c 1.5, MeOH );
 1H 
NMR (500 MHz, CDCl3): 5.83-5.87 (m, 1H), 5.60 (ddd, J = 1.5, 6.7, 15.1 Hz, 1H), 4.55-
4.59 (m, 1H), 4.33 (t, J = 3.0 Hz, 1H), 4.25 (dd, J = 3.7,  6.7 Hz, 1H), 2.93 (dd, J = 6.7, 
18.1 Hz, 1H), 2.51 (dd, J = 3.0, 18.1 Hz, 1H), 1.75 (d, J = 6.7 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 175.3, 131.1, 128.1, 89.2, 72.6, 69.0, 38.1, 17.8.; HRMS: m/z calcd for 
C8H12O4Na [M+Na]
+: 195.06278; found: 195.06205. 
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1H NMR Spectrum of compound 64 in CDCl3 (500 MHz) 
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 1H NMR Spectrum of compound 66 in CDCl3 (500 MHz) 
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1H NMR Spectrum of compound 67 in CDCl3 (500 MHz) 
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NOESY Spectrum of compound 71 
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LCMS data of Catenioblin B (60) 
 
 
 
               Instrument        :      LCMS-2020 SHIMADZU 
             Software            :      Lab Solutions ( 5.41.240 Version) 
              Sample Code     :     PRK-TS 
              Mobile Phase    :     Acetonitrile : 10 mm Ammonium acetate (pH 4.5 )  (60 :40 ) 
              Flow rate           :      1 mL/min 
             Column               :     XBridge -C 18 
             Column Size       :     4.6x150 mm 
            Particle Size        :    3.5 µ    
            Peak Table:        
Peak# Ret. Time Area Height Area% 
1 3.019 222098 13415 2.750 
2 6.958 7855464 693062 97.250 
Total  8077562 706477 100.000 
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3.1 Isolation and structure elucidation of Musacin F 
           γ-Butyrolactones occur ubiquitously in nature as subunits of miscellaneous natural 
products have been isolated from different sources such as microbes, fungi, plants, insects, 
and marine organisms, and some of these compounds and/or their derivatives exhibit strong 
biological activities.1 A number of methods have been developed for the synthesis of γ-
butyrolactone containing compounds in the light of their biological importance.2 The effort 
to develop efficient, practical, environment friendly, and low cost approaches relies on the 
design of effective synthetic methodologies. 
           New secondary metabolites of musacins A-F, which are highly functionalized γ-
butyrolactones including their open ring derivatives collectively isolated from 
Streptomyces griseoviridis (FHS1832)3. However, the relative and absolute configuration 
of the three stereogenic centers of the musacins has not been determined. Recently, the 
marine-derived fungus Nigrospora sphaerica PSU-F18 from which the ethyl acetate extract 
culture broth exhibited interesting antibacterial activity against standard Staphylococcus 
aureus ATCC 25923(SA) and S. aureus (MRSA) also led to isolation of four new 
nigrosporapyrones A-D pyrones together with some known compounds including musacin 
F, tyrosol, solanapyrone A, phomalactone etc.4 Accordingly, in the present research we 
have developed a synthetic route for one of γ-butyrolactone structural unit i.e musacin F 
(73). 
The musacin F (73)3,4 structure was determined by spectroscopic analysis. It is a sticky 
light yellow oil, the molecular formula C8H12O4 was suggested from the EI-MS (70 eV) 
(abundance, %) 172 (3, [M+]). The 1H NMR spectrum in CD3OD exhibited signals at δ 
4.45 (ddd, J = 7.0, 1.5 and 1.5 Hz, 3-H), δ 4.29 (dd, J = 3.0, 1.5 Hz, 4-H ) and δ 4.24 (m, 5-
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H) for three oxygenated methines, the double bond was proposed to be trans by a pair of 
olefinic signals at δ 5.86 (dqd, J = 15.5, 6.5 and 1.5 Hz, 7-H) and δ 5.53 (dqd, J = 15.5, 6.0 
and 1.5 Hz, 6-H,) for a methylene and the terminal methyl group protons at δ 1.74 (ddd, J = 
6.5, 1.5 and 1.5 Hz, 8-H3). The 
13C NMR spectrum indicated the presence of an ester 
carbonyl carbon (δ 179.1), three oxygenated methines (δ 92.4, 72.7, and 68.0), and trans 
double bond (δ 130.0 and 130.0). In conclusion, the structure of musacin F (73) was 
established as depicted (Figure 3.1). 
Hence, musacin F (73) is closely related to catenioblin B5 i.e the same synthetic strategy 
used to synthesize the catenioblin B (chapter 2) will be applied to synthesize the target 
molecule 73 
 
3.2 Retrosynthetic strategy 
 
The retrosynthetic analysis for musacin F (73) is illustrated in scheme 3.1. Our approach is 
based on the use of the Sharpless asymmetric dihydroxylation as a synthetic tool to access 
the polyol system en route to the crucial compound 82, that in turn could be conceived to 
arise from α,β-unsaturated ester 74 via a sequence of transformations of Sharpless 
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asymmetric dihydroxylation, followed by a Grignard reaction, oxidation and Luche 
reduction that would be used for the formation of polyol system. Further extensions would 
involve the protection of allylic alcohol as the MOM-ether and subsequent deprotection of 
the PMB-ether to achieve the formation of compound 82. Finally, the furanone ring 
cyclization could be constructed under acidic conditions and deprotection of the methoxy 
ether would furnish the natural product.  
3.3 Results and Discussion 
Initially, the advanced intermediate 74 (Scheme 3.2) was accessed from the same α,β-
unsaturated ester 74 used in the previous synthesis described in chapter 2.6 Accordingly, 
the α,β-unsaturated ester 74 upon the enantioselective Sharpless asymmetric 
dihydroxylation using  (AD-mix-β/tBuOH/H2O) at 0 oC to rt stirred for 8 h gave the diol 75 
in over 86% yield and 96% ee.7 The ee was achieved by the enantiomerically-enriched 
chiral ligand [(DHQD)2PHAL] and the syn stereochemistry of diol was determined after it 
was converted into an isopropylidene derivative (Scheme 3.3, 3.4). The compound 75 was 
confirmed from the 1H NMR spectrum wherein the protons attached to the dihydroxy 
groups resonated at δ 3.09 and δ 2.97 ppm as a multiplet and the absence of olefinic 
protons further supported the formation of diol 75. The molecular structure was supported 
by MS HRMS m/z: calcd for C15H22O6Na [M+Na]
+: 321.1308 found: 321.1296.  
 
Then the diol 75 was masked as its acetonide by reaction with 2,2-dimethoxy propane and 
PPTS (cat.) in CH2Cl2 for 3 h, giving 76 in 92% yield (Scheme 3.3). In the 
1H NMR 
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spectrum the acetonide protons resonated at δ 1.46 ppm and δ 1.44 ppm as two singlets, 
while rest of the protons resonated at the expected chemical shifts supporting the formation 
of the acetonide 68. This was further confirmed by observing the 13C NMR signals for the 
geminal dimethyl groups of the isopropylidene ring of compound 76 which appeared at δ 
27.0 and 25.6 ppm and were in agreement with the nearly equivalence of the gem-dimethyl 
groups for the characteristic of the acetonide 76 in the syn-diol system as previously 
reported.8 The molecular structure was further supported by MS HRMS m/z: calcd for 
C18H30O6Na [M+Na]
+: 361.1729 found: 361.1608.  
 
Reduction of ester 76 with DIBAL-H in CH2Cl2 furnished the primary alcohol 77 in 86% 
yield (Scheme 3.4). In the 1H NMR spectrum of 77, the disappearance of -OCH2CH3 
protons resonating at δ 3.66-3.55 ppm, δ 1.27 (t, J = 7.1 Hz, 3H) and the appearance of the 
-CH2OH methylene at δ 1.91 (q, J = 6.2 Hz, 2H) indicates the formation of the primary 
alcohol. Here, also 13C NMR signals for the geminal dimethyl groups of the isopropylidene 
ring of compound 77 appeared at δ 27.2 and 26.9 ppm indicating the syn-stereochemistry 
of diol. IR spectrum of 77 showed the peaks at 3394 (O-H) cm-1. This was supported by 
MS HRMS m/z: calcd for C18H30O6Na [M+Na]
+: 319.1624 found: 319.1503. 
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Then, the primary alcohol 77 was subjected to Swern oxidation followed by a Grignard 
reaction9 (1-propenyl magnesium bromide/THF/0 oC) to afford the allyl alcohol 78 as 
syn/anti diastereomeric mixture along with its E,Z-isomers in 85% yield over two steps 
(Scheme 3.5). The separation of each of this syn/anti along with the E,Z-isomers was 
difficult, due to very close proximity on TLC. We decided to obtain the desired isomer 
from the mixture without separation after the oxidation. Thus, it was subjected to Dess-
Martin periodinane (DMP) oxidation to provide the α,β-unsaturated ketone as a separable 
(3:2) E/Z mixture 79a, 79b in a yield of 90%. The diastereomeric ratio was determined 
from the isolated yield that were separated by column chromatography to give E-isomer 
79a. The overall yield after isolation was 50% and the purified E-isomer was used for the 
next step. The structure confirmation was supported by the 1H NMR spectrum which 
revealed the presence of olefinic protons at δ 7.01-7.09 ppm as a multiplet and δ 6.55 as a 
doublet of doublet with a J = 15.5, 1.6 Hz separation supporting the trans geometry of the 
olefin in the oxidation product. The 13C NMR spectrum of the carbonyl carbon resonated at 
δ 197.1. The IR spectrum showed the frequency of α,β-unsaturated C=O bond at 1690 cm-1 
as the confirmation of ketone group.  The molecular structure was supported by MS HRMS 
m/z: calcd for C19H26O5Na [M+Na]
+: 357.1672 found: 357.1665. 
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The purified E-isomer 79a of the α,β-unsaturated ketone group (Scheme 3.6) was reduced 
under Luche reduction conditions10 (CeCl3. 7H2O/NaBH4/MeOH/-78 
oC) to afford chiral 
allylic alcohol 80 in 83% yield. The absolute stereochemistry at C5 was tentatively 
assigned as ‘S’ based on that previously discussed in chapter 2, i.e the selectivity obtained 
when cerium salts are mixed with NaBH4 is explained by a chelated intermediate 
favourable for the formation of hydroxyl group of 80 in syn orientation (C4-C5) with each 
other may result a major S-alcohol.11 Subsequently confirmed by extensive NMR as well as 
LCMS studies. This was characterized from the 1H NMR spectrum of 80 that revealed that 
the appearance of one peak δ 3.66-3.7 proton as a multiplet. The de of allylic alcohol 80 
was calculated as 95.7% by LCMS {column: XCB C18 column, 30% water (NH4OAc 10 
mm) in acetonitrile, flow rate: 1 mL/min, 254 nm, tr(major) = 9.555 min, tr(minor) = 8.843 
min} in favor of S-alcohol (major). The molecular structure was supported by MS HRMS 
m/z: calcd for C19H28O5Na [M+Na]
+: 359.1836 found: 359.1889. 
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The selection of the appropriate protecting group is important as it must be tolerant to 
reagents in subsequent steps; hence MOM protection was chosen for its stability under 
mild acidic conditions. This would enable selective deprotection of acetonide to be 
achieved while retaining MOM group and that forms a 5-membered lactone ring formation 
instead of 6-membered. To achieve this, compound 80 was treated with MOM-Cl (methoxy 
methylene chloride) under basic conditions using DIPEA (N,N-diisopropylethylamine) and 
DMAP(cat) in dry CH2Cl2 at 0 
oC-rt for 4 h afforded the allyl alcohol 81 in 89% yield 
(Scheme 3.7). The structure of compound 81 was confirmed by spectroscopic analysis. The 
1H NMR revealed protons pertaining to MOM-group for instance the diastereotopic OCH2 
protons appeared as an apparent doublet at δ 4.43 ppm,  and the OCH3 protons resonated at 
δ 3.36 ppm as a singlet. The compound 81 was also supported by mass spectral analysis, 
MS HRMS m/z: C21H32O6Na [M+Na]
+: 403.3091, found 403.2083. 
 
The p-methoxybenzyl (PMB) group of 81 was deprotected under mildly oxidizing 
conditions using DDQ (dichlorodicyanobenzoquinone) (Scheme 3.8) gaving the primary 
alcohol 82 quantitative yield 93%. Further, it was confirmed by the 1H NMR spectrum, 
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which revealed that the absence of aromatic peaks corresponding to 4-methoxy benzoyl 
group and also supported by MS HRMS m/z: C13H24O5Na [M+Na]
+: 283.1516, found 
283.1522. 
 
Finally, the primary alcohol 82 was oxidized (Scheme 3.9) to its corresponding carboxylic 
acid using the reagents TEMPO and BAIB in a mixture of solvents CH2Cl2:H2O (1:1) at 0 
oC-rt for 4 h to afford 83 in yield 90%.5,12 The crude material was directly used for the 
further steps without purification. 
 Here, we applied two synthesis pathways to product 73 for comparing the formation of 5-
membered ring instead of 6-membered ring. In some cases the ideal bond angles for an sp3 
carbon are 109.5 degrees.  In a 5-membered ring, the bond angles are somewhat less than 
109.5 degrees, which causes bond angle strain.  The relative ring strain in question is the 
greater bond angle strain in the 5- than the 6-membered ring, therefore favouring formation 
of the lactone. Thus, the 6-membered ring is more energetically favored. To avoid the 
formation of 6-membered ring and in order to retain MOM protection, we conducted a mild 
selective deprotection of the acetonide group in preference to MOM group for the 
exclusive formation of 5-membered lactone 84, which is confirmed by spectral data. Next, 
the deprotection of the MOM group gave the final target 73.  
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As an alternative approach, also conducted a global deprotection of all groups under the 5N 
HCl condition, which upon cyclisation gave the same target compound 73, which was 
compared with the spectral data.  
 
First, (Scheme 3.9) the crude material 83 directly dissolved in C6H6 to which was added a 
catalytic amount of the p-TSA that produced the cyclized product 84 in 81% yield.13 The 
formation of 84 was confirmed by 1H NMR and mass spectral analysis. The 1H NMR 
revealed that disappearance of acetonide protons and OCH2 protons and the appearance of 
the 2o ester proton at δ 4.61 ppm as doublet (J = 6.4 Hz, 2H), remaining protons appearing 
at their respective chemical shifts. In the IR spectrum of 84, appearance of strong 
absorption peak at 3468 due to presence of –OH and 1770 cm-1 corresponding to ester 
carbonyl was observed. It was confirmed by mass spectral analysis, MS (ESI) m/z 
C10H20O5N [M+NH4]
+: 234. 
Later, compound 84 was subjected to the MOM ether deprotection under solvent free 
condition with phosphomolybdic acid on silica (PMA-silica) solvent free reaction14 to 
obtain the final product of musacin F 73 in 87% yield (Scheme 3.10). Formation of 
compound 73 was confirmed by 1H NMR wherein the protons due to MOM-group, the 
4.43 ppm as a  doublet and singlet at δ 3.36 ppm disappeared while rest of the protons 
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resonated at their expected chemical shifts. Further confirms the formation of the product 
by MS HRMS m/z C8H12O4Na [M+Na]
+:195.0628, found 195.0628. 
 
Second, the requisite γ-lactone functionality was generated with concomitant removal of 
acetonide group as well as MOM ether deprotection and followed by lactonization in one 
pot by adding 5N HCl (1 mL) to the crude material 83 to furnish target molecule musacin F 
(73) in 69% yield (Scheme 3.11) respectively.15 
 
The spectral data of the synthetic sample did not match with the reported natural product 
(Table 3.1).3,4 
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Table 3.1. 1H and 13C NMR data of natural product as well as synthetic product. 
Position        Natural product                               Synthetic product     
                δ 13C         1H, J in Hz                                                                δ 13C      1H, J in Hz   
1 179.1       175.5 
2α  39.5 2.30 dd (18.7, 1.5)     39.1 2.63 dd (17.8, 2.8)  
2β  2.84 dd (18.0, 7.0)     2.82 dd (17.8, 6.5) 
3  68.0 4.45 ddd (7.0, 1.5 and 1.5)     69.0 4.67 m 
4  92.4 4.29 dd (3.0, 1.5)       84.9 4.57 dd (3.8, 7.1) 
5  72.7 4.24 m       71.4 4.36 m  
6 130.0 5.86 dqd (15.5, 6.5 and 1.5)   130.8 5.86 dqd (15.4, 7.3 and 1.5) 
7 130.0 5.53 dqd (15.5, 6.0 and 1.5)   128.0 5.93 dqd (15.4, 7.3 and 1.5 ) 
8 18.1 1.74 ddd (6.5, 1.5 and 1.5)     17.8 1.74 ddd (6.5, 1.5 and 1.5)  
3.4 Conclusions 
Unfortunately, the NMR spectra of synthetic 73 differ significantly from the data for the 
natural sample. Inspection of the assigned spectra of the natural sample raises doubts as to 
the validity of its structural assignment. There are many possible reasons like natural 
product is in fact different to the synthetic product. Compounds which contain hydroxyl 
groups have NMR spectra which are sensitive to solvent and to concentration, this is 
because of the effects of intramolecular H-bonding to solvent and to concentration. We 
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need to run the NMR of our synthetic 73 at various concentrations to determine how 
sensitive/responsive the chemical shifts are to changes in sample concentration. Is there a 
solution to the data disparity by recording the NMR of an ‘optimal’ sample concentration? 
Another possibility to explore arises from the fact that the coupling constants to H-4 in the 
natural product are 3.0 and 1.5 Hz, however, our synthesized product coupling constants 
were found to be 7.7 and 3.8 Hz that implies an alternative conformation.  Perhaps the 
natural product configuration is inverted at C5 or alternatively is unchanged, instead C4 
and C3 are inverted. Selective protection of the natural product musacin F, allylic chiral 
C5OH followed by Mosher’s acid derivatisation would be helpful to resolve the 
configuration C3OH chiral alcohol. Ultimately an X ray crystal structure analysis of either 
or both musacin F compounds/derivatives would solve the 3D structure of musacin F. 
And, in some cases we can find the problems by making possible isomer based on impact 
of that natural product. 
In summary, we have accomplished the first total synthesis of musacin F 73 in 10 to 11 
steps with an overall yield 12.3 to 14.0%, featuring a Sharpless asymmetric 
dihydroxylation, Grignard reaction followed by Luche reduction and intramolecular 
cyclization under acidic conditions as the key reaction steps. Our reliance as asymmetric 
chiral catalyst and chiral auxiliaries to dictate in a synthesis provided a substantial 
flexibility. This study demonstrates the important role of stereoselective total synthesis in 
structure determination of complex natural products.16 Moreover, this synthetic pathway 
will allow to synthesis of other isomers for more detailed studies towards the natural 
product structure. Hence a structural revision was felt necessary. 
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3.5 EXPERIMENTAL PROCEDURE 
3.5.1 Ethyl (2S,3R)-2,3-dihydroxy-5-((4-methoxybenzyl)oxy) pentanoate (75)  
 
To a stirred solution of (Scheme 3.2) a mixture of unsaturated ester 74 (5 g, 18.9 mmol), 
tBuOH/H2O (1:1, 60 mL), methanesulfonamide (0.18 g, 1.89 mmol), and AD-mix-β (26.5 
g, 22 mmol) was stirred vigorously for 8 h and then quenched with solid Na2SO3 (3 g) at 0 
°C and the mixture was stirred at 20 °C for 30 min. The precipitate was filtered off and the 
solution diluted with water (100 mL) and extracted with EtOAc. The combined organic 
extracts were washed with aqueous HCl (1M) and with brine, and dried with Na2SO4. 
Removal of solvent in vacuo afforded the crude diol, which was purified by silica gel 
column chromatography (Silica gel, 60-120 mesh, EtOAc:n-hexane, 50:50) to furnish an 
inseparable 93:7 diastereomeric mixture (identified from 1H NMR spectrum) of 75 as pale 
yellow oil (4.8 g, 86%). []
25
D  = +9.2 (c 0.8 , CHCl3); 
1H NMR (300 MHz, CDCl3): δ 7.24-
7.27 (m, 2H), 6.86-6.89 (m, 2H), 4.46 (s, 2H), 4.32-4.20 (m, 2H), 4.19-4.16 (m, 1H) , 4.06 
(dd, J = 6.7, 2 Hz, 1H), 3.80 (s, 3H), 3.66-3.55 (m, 2H), 3.13-3.11 (m, 1H), 2.9 (d, J = 6.3 
Hz, 1H), 2.05-2.01 (m, 1H), 1.85-1.81 (m, 1H), 1.32 (t, J = 7.3 Hz, 3H) ; 13C NMR (75 
MHz, CDCl3): δ 173.1, 159.3, 129.3, 113.8, 73.5, 73.0, 71.6, 67.8, 61.9, 55.3, 33.2, 14.2; 
MS HRMS m/z: calcd for C15H22O6Na [M+Na]
+: 321.1308 found: 321.1296.  
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3.5.2 Ethyl (4S,5R)-5-(2-((4-methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolane-4-
carboxylate (76)  
 
A solution of  (Scheme 3.3) diol 75 (4.5 g, 15.16 mmol) in dry CH2Cl2 (20 mL) at 0 °C 
PPTS (cat.) was added and the solution stirred for 20 min, and then 2,2-DMP (2.2 mL, 
18.12 mmol) was added and the solution stirred for additional 3 h. The reaction mixture 
was quenched with Et3N (4 mL) and concentrated in vacuo. The crude residue was purified 
by column chromatography (Silica gel, 60-120 mesh, EtOAc:n-hexane, 10:90) to afford 76 
(4.71 g, 92%) as a pale yellow oil. []
25
D  = +19.3 (c 1.0 , CHCl3); 
1H NMR (500 MHz, 
CDCl3): δ 7.25 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.43 (s, 2H), 4.31-4.16 (m, 
4H), 3.80 (s, 3H), 3.66-3.55 (m, 2H), 2.16-1,98 (m, 1H), 1.97-1.93 (m, 1H), 1.46 (s, 3H), 
1.44 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 170.5, 159.3, 130.3, 
129.1, 113.6, 110.4, 79.0, 76.3, 72.6, 66.2, 61.3, 55.2, 33.5, 27.0, 25.6, 14.1; MS HRMS 
m/z: calcd for C18H30O6Na [M+Na]
+: 361.1729 found: 361.1608.  
3.5.3 ((4R,5R)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)methanol (77)  
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To a cooled (0 °C) solution of 76 (Scheme 3.4) (4 g, 11.83 mmol) in dry CH2Cl2 (15 mL), 
DIBAL-H (13.04 mL, 23.66 mmol, 25% solution in toluene) was added slowly. The 
reaction mixture was stirred at the same temperature for 3 h, at the same temperature, the 
reaction mixture was quenched with methanol (2 mL) and sat. aq. solution of sodium 
potassium tartrate (10 mL). The reaction mixture was filtered through a short pad of celite 
and the pad was further washed with CH2Cl2 (3 x 40 mL). The filtrate was dried (Na2SO4) 
and concentrated then, the residue was purified by column chromatography (Silica gel, 60-
120 mesh, EtOAc:n-hexane, 30:70) to furnish 77 (3.01 g, 86%) as a colorless liquid. []
25
D  
= -12.7 (c 0.9, CHCl3);
 1H NMR (300 MHz, CDCl3): δ 7.25 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 
8.4 Hz, 2H),  4.44 (s, 2H), 3.96-4.08 (m, 1H), 3.86-3.72 (m, 5H), 3.69-3.51 (m, 3H), 1.91 
(q, J = 6.2 Hz, 2H), 1.4 (s, 6H); 13C NMR (125 MHz): δ 159.2, 130.1, 129.3, 113.8, 108.5, 
81.3, 74.9, 72.7, 66.7, 62.0, 55.2, 33.2, 27.2, 26.9.; MS HRMS m/z: calcd for C18H30O6Na 
[M+Na]+: 319.1624 found: 319.1503. 
3.5.4 1-((4R,5R)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)but-2-en-1-ol (78)  
 
To a solution of oxalyl chloride (Scheme 3.5) (1.2 mL, 13.68 mmol) in dry CH2Cl2 (12 
mL) at -78 0C, dry DMSO (1.94 mL, 27.36 mmol) was added drop wise and stirred for 10 
min. A solution of primary alcohol 77 (2.7 g, 9.12 mmol) in dry CH2Cl2 (8 mL) was added 
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and stirred for 2 h at -78 0C. It was quenched with Et3N (7.6 mL, 54.72 mmol) and diluted 
with CH2Cl2 (30 mL). The reaction mixture was washed with water (20 mL), brine (10 
mL), dried (Na2SO4) and evaporated to furnish the corresponding aldehyde.  
To a stirred solution (Scheme 3.4) of aldehyde (2 g, 6.8 mmol) in THF (10 mL), 1-propenyl 
magnesiumbromide 0.5M (26 mL, 9.2 mmol) were added at 0 °C. Then sat. aq. NH4Cl (8 
mL) was added slowly and stirred for 2 h. Later, quenched with aq. sat. NH4Cl (20 mL), 
extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine 
(20 mL), dried (Na2SO4) and concentrated in vacuo. The crude residue was purified by 
column chromatography (Silica gel, 60-120 mesh, EtOAc:n-hexane, 25:75) to afford 78 
(1.94 g, 85%). Used for directly next step, due to difficult in separation of desired isomer. 
3.5.5 (E)-1-((4S,5R)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)but-2-en-1-one (79a)  
 
To a stirred solution (Scheme 3.5) of alcohol 78 (1.5 g, 4.46 mmol) in anhydrous CH2Cl2 
(10 mL) under N2 atmosphere at 0 °C Dess-Martin periodinane (2.27 g, 5.35 mmol) was 
added and reaction mixture stirred at room temperature for 2 h. After that quenched with 
1:1 mixture of aq. sat. solution of  Na2S2O3 and NaHCO3 (6 mL), then extracted with 
CH2Cl2 (2 x 30 mL), the combined organic layer was washed with water (20 mL), brine (20 
mL), dried over (Na2SO4), concentrated and the crude residue was formed as E/Z-mixture 
purified by column chromatography (Silica gel, 60-120 mesh, EtOAc:n-hexane, 10:90) to 
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afford E-isomer ketone 79a (0.74 g, 50%) as a yellow oil. []
25
D  = -0.80 (c 2.5, CHCl3);
  1H 
NMR (500 MHz, CDCl3): δ 7.23 (d, J = 8.5 Hz, 2H), 7.01-7.09 (m, 1H), δ 6.86 (d, J = 8.6 
Hz, 2H), 6.55 (dd, J = 1.6, 15.5 Hz, 1H), 4.4 (s, 2H), 4.18-4.23 (m, 2H), 3.80 (s, 3H), 3.53-
3.66 (m, 2H), 1.93-1.99 (m, 1H), 1.90-1.92 (m, 1H), 1.45 (s, 3H), 1.42 (s, 3H); 13C NMR 
(75 MHz, CDCl3): δ 197.1, 159.0, 130.4, 129.2, 126.8, 113.6, 110.1, 83.9, 75.6, 72.5, 66.3, 
55.2, 33.5, 29.6, 27.1, 26.1, 18.5; MS HRMS m/z: calcd for C19H26O5Na [M+Na]
+: 
357.1672 found: 357.1665. 
 3.5.6 (S,E)-1-((4R,5R)-5-(2-((4-Methoxybenzyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-
4-yl)but-2-en-1-ol (80)  
 
To a stirred solution (Scheme 3.6) of α,β-unsaturated ketone 79a (0.70 g, 2.09 mmol) and 
CeCl3·7H2O (0.196 g, 0.52 mmol) were dissolved in MeOH (5 mL) and cooled to 0 °C. 
NaBH4 (0.082 g, 2.09 mmol) was dissolved in MeOH (5 mL) and added within 5 mins to 
the reaction solution via a dropping funnel. After complete addition of the NaBH4 solution 
the cooling bath was removed and the reaction continued. TLC control (hexane:EtOAc = 
70:30) after 4 h revealed complete conversion of the starting material and the reaction was 
treated with 2N HCl (5 mL) and extracted with Et2O (3 x 20 mL). The organic phase was 
dried over Na2SO4, filtered and the solvent was removed under reduced pressure. Purified 
by column chromatography (n-hexane:EtOAc = 70:30) yielded (0.58 g, 83%) of allyl 
alcohol 80 as a slightly yellow oil. []
25
D  = +4.55 (c 2.2, CHCl3);
 1H NMR (500 MHz, 
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CDCl3): δ 7.25 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 5.71-5.79 (m, 1H), 5.43 (ddd, 
J = 1.6, 7.7, 15.4 Hz, 1H), 4.43 (s, 2H), 4.04-3.98 (m, 2H), 3.80 (s, 3H), 3.66-3.7 (m, 1H), 
3.52-3.63 (m, 2H), 1.88-1.95 (m, 1H), 1.79-1.87 (m, 1H), 1.70 (d, J = 7.3, 3H), 1.40 (s, 
6H); 13C NMR (125 MHz, CDCl3): δ 159.1, 130.3, 129.7, 129.2, 113.7, 108.8, 83.7, 75.0, 
72.6, 66.8, 55.2, 33.6, 29.6, 27.4, 27.1, 17.8; MS HRMS m/z: calcd for C19H28O5Na 
[M+Na]+: 359.1836 found: 359.1889. 
3.5.7 (4R,5S)-4-(2-((4-Methoxybenzyl)oxy)ethyl)-5-((S,E)-1-(methoxymethoxy)but-2-
en-1-yl)-2,2-dimethyl-1,3-dioxolane (81)  
 
 
To a stirred solution of (Scheme 3.7) compound 80 (0.5 g, 1.48 mmol) in anhydrous 
CH2Cl2 (6 mL) at 0 °C under nitrogen was added DIPEA (0.8 mL, 4.46 mmol) and 
MOMCl (0.2 mL, 1.78 mmol) in the presence of a catalytic amount of DMAP, and the 
mixture was stirred for 6 h at room temperature Then, the mixture was concentrated under 
reduced pressure and subjected to column chromatography (Silica gel, 60-120 mesh, 
EtOAc:n-hexane = 15:85) to obtain 81 (0.5 g, 89%) as a yellow liquid.  []
25
D  = +21.69 (c 
0.5, CHCl3);
 1H NMR (300 MHz, CDCl3): δ 7.25 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 
2H), 5.67-5.87 (m, 1H), 5.26-5.37 (m,1H), 4.74 (d, J = 6.6 1H), 4.55 (d, J = 6.6 Hz, 1H), 
4.43 (s, 2H), 3.95-4.08 (m, 2H), 3.81 (s, 3H), 3.72-3.80 (m, 1H), 3.51-3.66 (m, 2H), 3.36 
(s, 3H), 1.88-2.05 (m, 1H),1.74-1.86 (m, 1H), δ 1.72 (d, J = 7.9 Hz, 3H), 1.40 (s, 6H); 13C 
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NMR (125MHz, CDCl3): δ 159.0, 132.1, 130.5, 129.1, 126.7, 113.6, 108.8, 92.9, 82.6, 
74.9, 72.5, 66.9, 55.2, 33.8, 31.9, 29.6, 27.4, 26.9, 22.6, 17.8; MS HRMS m/z: C21H32O6Na 
[M+Na]+: 403.3091, found 403.2083. 
3.5.8 2-((4R,5S)-5-((S,E)-1-(Methoxymethoxy)but-2-en-1-yl)-2,2-dimethyl-1,3-
dioxolan-4-yl)ethan-1-ol (82)  
 
To a stirred solution of (Scheme 3.8) PMB ether 81 (0.45 g, 1.19 mmol) in CH2Cl2:H2O 
(19:1) (5 mL) was added DDQ (0.32 g, 1.4 mmol) at 0 °C and reaction mixture stirred at 
room temperature for 4 h. Then aq. sat. NaHCO3 (2 mL) was added and extracted with 
CH2Cl2 (2 x 10 mL), the combined organic layer was washed with water (10 mL), brine (10 
mL), dried (Na2SO4), concentrated and the crude residue was purified by column 
chromatography (Silica gel, 60:120, EtOAc:n-hexane = 30:70) to afford alcohol 82 (0.28 g, 
93%) as yellow oil. []
25
D  = +24.69 (c 0.7, CHCl3);
 1H NMR (500 MHz, CDCl3): 5.75-5.83 
(m, 1H), 5.33 (ddd, J = 1.5, 7.8, 15.7 Hz, 1H), 4.75 (d, J = 6.5 Hz, 1H), 4.57 (d, J = 6.7 Hz, 
1H), 4.01-4.10 (m, 2H), 3.77-3.83 (m, 3H), 3.38 (s, 3H), 1.85-1.93 (m, 1H), 1.77-1.83 (m, 
1H), 1.72 (dd, J = 6.5, 1.5 Hz, 3H), 1.43 (s, 3H), 1.41 (s, 3H); 13C NMR (125 MHz, 
CDCl3): δ 132.3, 126.4, 109.2, 93.0, 82.5, 60.9, 55.3, 35.6, 27.3, 26.8, 17.8; MS HRMS 
m/z: C13H24O5Na [M+Na]
+: 283.1516, found 283.1522. 
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3.5.9 (4R,5S)-4-Hydroxy-5-((S,E)-1-(methoxymethoxy)but-2-en-1-yl)dihydrofuran-
2(3H)-one (84)  
 
First route, to a stirred solution of 82 (Scheme 3.9) (0.2 g, 0.76 mmol) in CH2Cl2:H2O (1:1, 
2 mL) was added TEMPO (cat.) and BAIB (0.37 g, 1.2 mmol) successively at 0 °C and 
allowed to stir at room temperature for 4 h. Later, the reaction mixture was quenched with 
sat. aq. Na2S2O3 (1 mL) and extracted with CH2Cl2 (2 x 10 mL). The combined organic 
layers were washed with water (5 mL), brine (5 mL), dried (Na2SO4) and evaporated. Then 
the crude material of compound 83 was directly dissolved in C6H6 and added the catalytic 
amount of the p-TSA and stirred at room temperature for 2 h obtained a cyclized product 
84 and the crude residue was purified by column chromatography (Silica gel, 60: 120, 
EtOAc:n-hexane, 25:75) to afford pure 84 (0.13 g, 81% overall two steps) as slightly 
yellow liquid.  []
25
D  = +40.06 (c 0.5, CHCl3 );
 1H NMR (300 MHz, CDCl3): 5.82-5.99 (m, 
1H), 5.48-5.59 (m, 1H), 4.71 (d, J = 6.4 Hz, 1H), 4.61 (d, J = 6.4 Hz, 2H), 4.38-4.51 (m, 
2H), 3.41 (s, 3H), 3.01 (br, 1H), 2.79 (dd, J = 6.7 Hz, 1H), 2.64 (dd, J = 4.1 Hz, 1H), 1.78 
(d, J = 7.9 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 174.7, 133.2, 125.6, 93.5, 84.1, 75.3, 
68.6, 55.7, 38.3, 17.8; MS-ESI: m/z C10H20O5N [M+NH4]
+:234. 
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3.5.10 (4R,5S)-4-Hydroxy-5-((S,E)-1-hydroxybut-2-en-1-yl)dihydrofuran-2(3H)-one 
(73) 
 
Simultaneously, to the compound 84 (0.032 g, 0.12 mmol) was added PMA-silica (cat.) 
(Scheme 3.10) at room temperature under neat condition allowed to stir for 4 h. Then the 
reaction mixture was filtered through a celite pad with EtOAc (20 mL), the celite pad was 
further washed with the EtOAc (2 x 20 mL) the combined organic layers was washed with 
water (10 mL), brine (12 mL), and dried over (Na2SO4), concentrated and the crude residue 
was purified by column chromatography (Silica gel, 60-120 mesh, EtOAc:n-hexane, 55:45) 
to afford final compound of the musacin F 73 (0.017 g, 87%) as a yellow oil.  
Second route, (Scheme 3.11) the solution of 5N HCl (1 mL) was directly added to the 
crude compound 83 (0.05 g, 0.21 mmol) at 0 oC and then the reaction mixture was stirred 
for 1 h at the same temperature. After completion of the reaction extracted with EtOAc (3 
mL) and the crude residue was purified by the column chromatography (Silica gel, 60-120 
mesh, EtOAc:n-hexane = 55:45) to afford final target the musacin F 73 (0.025 g, 69%) as a 
yellow oil. []
25
D  = +41.23 (c 0.5, CHCl3 );
 1H NMR (500 MHz, CDCl3): 5.93 (dqd, J = 
15.4, 7.3 and 1.5 Hz, 1H), 5.86 (dqd, J = 15.5, 6.5 and 1.5, 1H), 4.65-4.69 (m, 1H), 4.57 
(dd, J = 3.8, 7.1 Hz, 1H), 4.33-4.38 (m, 1H), 2.82 (dd, J = 17.8, 6.5 Hz, 1H), 2.63 (dd, J = 
17.8, 2.8 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 175.5, 130.8, 128.0, 84.9, 71.4, 69.0, 
39.1, 17.8; MS HRMS m/z C8H12O4Na [M+Na]
+:195.0628, found 195.0628. 
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1H NMR Spectrum of compound 75 in CDCl3 (300 MHz) 
 
13C NMR Spectrum of compound 75 in CDCl3 (75 MHz) 
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1H NMR Spectrum of compound 76 in CDCl3 (500 MHz) 
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1H NMR Spectrum of compound 77 in CDCl3 (500 MHz) 
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1H NMR Spectrum of compound 79a in CDCl3 (500 MHz) 
 
 
13C NMR Spectrum of compound 79a in CDCl3 (125 MHz) 
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1H NMR Spectrum of compound 80 in CDCl3 (500 MHz) 
 
 
13C NMR Spectrum of compound 80 in CDCl3 (125 MHz) 
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1H NMR Spectrum of compound 81 in CDCl3 (300 MHz) 
 
 
13C NMR Spectrum of compound 81 in CDCl3 (125 MHz) 
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1H NMR Spectrum of compound 82 in CDCl3 (500 MHz) 
 
 
13C NMR Spectrum of compound 82 in CDCl3 (125 MHz) 
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1H NMR Spectrum of compound 84 in CDCl3 (75 MHz) 
 
13C NMR Spectrum of compound 84 in CDCl3 (125 MHz) 
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1H NMR Data of compound 73 in CDCl3 (500MHz) 
 
 
 
 
 
 
 
13C NMR Spectrum of compound 73 in CDCl3 (75 MHz) 
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HRMS Spectrum of compound 73 
 
 
CHAPTER-IV
SYNTHESIS, STUDY OF BIOLOGICAL PROPERTIES OF DIVERSE
POLYPHENOL TRIAZINES
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4.1 INTRODUCTION  
      
           Over the last few decades, age-related diseases such as dementia and Alzheimer’s disease 
(AD) have evolved into a global epidemic in a growing aging population. The risk of AD is 
highest in people aged over 65, and is predicted to grow by 62% between 2015 and 2030 to 
around 1 billion worldwide.1 AD is a neurodegenerative disorder characterized by progressive 
and irreversible impairment of memory and other cognitive functions. Previous reports suggest 
that pathological deterioration of AD patients has been associated with extra cellular cerebral 
accumulation of insoluble aggregates of amyloid-β peptides (Aβ) and intracellular 
hyperphosphorylated and tangled tau protein.2 Aβ peptide has been associated with number of 
other neurotoxic pathways that lead to formation of reactive oxygen species (ROS), disruption of 
homeostasis and Ca2+ balance.3 
Amyloid is a term for typically ordered β-sheet proteins, they are often insoluble, mis-folded 
fibril protein aggregates associated with certain pathological events. One prominent strategy to 
reduce neurodegeneration has thus emphasized the removal of neurotoxic Aβ oligomers by 
implementing small-molecule aggregation modulators that interrupt π−π stacking between β-
sheets in order to inhibit Aβ self-association.4 These prefibril oligomeric species have been 
identified as the more potent structures in Aβ-induced toxicity. A variety of small molecule 
aggregation inhibitors have been reported in the literature to prevent hydrophobic association 
and fibrillogenesis of Aβ by disrupting β-sheet π−π stacking.5 
     AD is mainly characterized by the deposition of amyloid in affected neurons and in 
cholinergic neurotransmission deficit in the brain. The current therapeutic intervention for AD is 
primarily based on the inhibition of brain acetylcholinesterase (AChE) to sustain the brain 
acetylcholine levels. The discovery of anti-amyloidogenic safe substances that prevent Aβ 
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misfolding and its gain in toxic function may provide a therapeutic window to combat cognitive 
impairment and dementia diseases.6 The complementation of lifestyle choices with anti-
amyloidogenic compounds and food supplements is a practical and personal strategy to improve 
protection against dementia to combat the epidemic of cognitive decline, a hallmark of aging.7 
Also, the currently available treatments, eg, aricept and memantine, usually provide at best only 
temporary and incomplete symptomatic relief. The current therapies provide marginal benefits 
and emphasize the urgent need to develop effective disease-modifying AD treatments. In recent 
years remarkable efforts have been expended in developing small molecules that are capable of 
inhibiting Aβ aggregation. Mainly the inhibition of Aβ aggregation requires blocking 
interactions between Aβ monomers, and historically, protein–protein interaction interfaces are 
particularly difficult drug targets.8 The challenges associated with targeting Aβ aggregation are 
substantial, with the most obvious obstacle being the sheer size, steric hindrance and geometry of 
the protein interaction surface.9 The binding energy that drives protein–protein contacts is 
typically distributed over a large area that lacks a defined “hotspot” for pharmacological 
intervention.10 48 Together, these problems place severe restrictions on the development of Aβ 
aggregation inhibitors. Studies have demonstrated that various Aβ peptide regions contribute 
differently to Aβ aggregation and have identified important interactions among specific peptide 
regions that control this process.11 For instance, Aβ41-42 are all crucial for the peptide’s ability 
to aggregate and promote neurotoxicity. As the strategy of inhibiting Aβ aggregation has 
increasingly gained acceptance, greater numbers of inhibitors have been developed and the 
structure-activity relationships of potent inhibitors have been systematically explored.12 Most of 
the studies revealed that typical Aβ aggregation inhibitors (Figure 4.1) such as Congo red (CR), 
chrysamine G (CG) and curcumin share a similar chemical scaffold.  
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Most of the small molecules designed according to these specifications would therefore be 
capable of inhibiting Aβ aggregation by binding to a specific sub-region. In our view, most 
inhibitors target only one sub-region. In fact, if inhibitors could target multiple specific sub-
regions in concert, they might act synergistically to effectively inhibit Aβ aggregation.  Thus, the 
ideal Aβ-targeting inhibitor should be of appropriate length and suitable flexibility, and should 
contain multiple groups that interact with Aβ residues. Some of small molecules that target 
specific Aβ sub-regions represent the first generation of amyloid-based therapeutics with the 
potential to demonstrate disease-modifying activity.  Although the results of ongoing clinical 
trials are inconclusive, these chemical compounds hold the promise of a new way for the 
development of disease-modifying therapies for AD. Alzheimer’s disease drugs and selected 
compounds in various stages of clinical trials are listed in Table 4.1 below. 
Chemical Compound  Structure Brief information  
Tideglusib 
 
 
Synthetic source 
Tau aggregation inhibitor pathway 
Phase II stage 
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PTB2 
 
Synthetic source 
Aβ aggregation inhibitor pathway 
Phase IIa stage 
 
Scyllo-inositol 
 
Natural source 
Aβ aggregation inhibitor pathway 
Phase II stage 
 
RS0406 
 
Synthetic 
Aβ aggregation inhibitor pathway 
 Phase IIa stage 
 
EGCG 
 
Natural source 
Aβ aggregation inhibitor pathway  
Phase IIa stage 
 
Tacrine 
 
 
Synthetic source 
AchE inhibitor pathway 
Marketing stage 
Donepezil 
 
Synthetic source 
AchE inhibitor pathway 
Marketing stage 
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Rivastigmine 
  
Synthetic (natural product inspired) 
AchE inhibitor pathway 
Marketing stage 
R-Flurbiprofen 
 
Synthetic 
Aβ plaques inhibitor pathway 
Phase III stage (failed) 
Table 4.1 
4.2 Polyphenols as inhibitors of Aβ fibrillation in AD disease 
Oxidative stress is a hallmark of AD disease and has been considered as a therapeutic target in 
diabetic patients for treatment.13 The increased oxidative stress can be characterized by stress 
markers such as DNA, RNA, lipid and protein oxidation in AD and cognitively impaired brains. 
These elevated oxidative stress markers precede amyloid deposition suggesting oxidative stress 
is an early event in AD pathogenesis.14 Firstly, mitochondria are a key player that produces 
reactive oxygen species (ROS). Mitochondrial dysfunction found in AD patients may also 
increase the production of ROS and oxidative stress. Second, amyloid-beta peptide generates 
ROS in the presence of metal ions such as Fe2+ and Cu2+. Furthermore, the content of iron and 
copper is increased in AD brains and these metal ions are able to stimulate formation of free 
radicals via the Fenton reaction.15 Therefore natural polyphenolic compounds such as green tea 
polyphenol anti-oxidants exhibit their neuroprotective effects through scavenging free radicals 
and facilitating the endogenous antioxidant system by stimulating transcription of antioxidant 
protective enzymes, superoxide dismutase and catalase. Moreover, these polyphenols exhibit 
their antioxidant action by chelating metal ions Fe2+ and Cu2+ and prevent the generation of free 
radicals via the Fenton reaction.16 
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          Green tea is one of the most popular and extensively used dietary supplements in the world 
and green tea extract contains several polyphenolic components with antioxidant properties,17 
including the predominant active components of the flavanol monomers known as catechins, 
epigallocatechin-3-gallate and epicatechin-3-gallate (Figure 4.2). Among these, (–)-
epigallocatechin-3-gallate18 (EGCG) is the most bioactive and has been proved to be effective in 
preventing the aggregation of Aβ in AD. EGCG has been shown to redirect the Aβ aggregation 
pathway and generate off- pathway non-toxic oligomers which are incapable of amyloid 
fibrillogenesis.19 EGCG can also remodel the mature Aβ fibrils into non-toxic oligomers,20 
suggesting its therapeutic potential for treatment of AD patients and it also attenuates the lipid 
peroxidation induced by the amyloid-beta peptides and protects against amyloid-beta-induced 
apoptosis by inhibiting caspase activation and enhances the hippocampal neuronal survival.  
 
The dye O4 (Figure 4.3) was found to bind directly to oligomers and promote the conversion into 
larger amyloid fibrils, by interacting with hydrophobic residues of Aβ1−42.21 ε-Viniferin 
glucoside (EVG; Figure 4.3) is one of the polyphenols that inhibits fibril formation in Aβ25−35, 
Aβ1−40, and Aβ1−42 that protects against PC12 cell death induced by these peptides.22 (+)-
Taxifolin,23 (Figure 4.3) is a flavonoid  and potential antagonist of Aβ aggregation inhibition.  
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Thus, we aimed to design rationally multifunctional new novel molecules that contain a sym-
triazine scaffold with polyphenol substitutions in one of the component to interfere with different 
key target points of AD neurodegeneration.  
4.3 sym-Triazine derivatives as multi target modulators of Alzheimer’s disease 
Previous reports suggest that s-triazine compounds can modulate multiple pathologies related to 
AD, specifically human acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and Aβ 
aggregation. The rational targeting of AChE was achieved by the incorporation of acetylcholine 
substrate analogues connected to the s-triazine core either in a mono-, di-, or tri-substituted 
regime (Figure 4.4). A subset of these derivatives demonstrated improved activity compared to 
several commercially available cholinesterase inhibitors.24 Some of the s-triazine analogs (Figure 
4.4) exhibited fibril inhibition of the β-sheet-disrupting penta-peptide, iAβ5p. Moreover, these s-
triazine compounds interact well with a number of amino acids located both at the C- and N-
terminal of Aβ-dimer. 
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4.4 Other biological properties of 2,4,6-substituted–1,3,5-triazine derivatives 
1,3,5-Triazine derivatives have received noteworthy attention owing to their broad biological 
activities, which have made it an essential anchor for development of new therapeutic agents. It 
has been extensively reported that the 2, 4 and 6 positions in 1,3,5-triazine bound to amide 
functions25 and also the presence of sulfonamide, morpholine, or pyrimidyl moieties show 
different kinase inhibition (Scheme 4.1) including phosphoinositide 3-kinases, protein kinase B, 
phosphoinositide dependent kinase, DNA dependent protein kinase, receptor tyrosine kinases, 
focal adhesion kinase, cyclin-dependent kinases and rho-associated protein kinases. Many of 
these molecules demonstrate remarkable pharmacokinetics based on the structure-activity 
relationship of the 1,3,5-triazine derived compounds for antitumor activity.26  
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4.5 Some triazine and natural polyphenol compounds are iron chelators  
Iron-chelation therapy has its origins in the treatment of iron-overload syndromes. Clinically 
approved indications for iron chelation are currently limited. Deferasirox is (Figure 4.5) a 
tridentate triazole polyphenol with iron chelating activity and is used for the treatment of iron 
excess in over transfused patients or less commonly in hereditary iron overload diseases and 
infrequently in acute iron intoxications.27 
Only Bis-(hydroxyamino)triazines (BHT’s) (Figure 4.5) are highly versatile group of tridentate 
iron(III) chelating agents exhibiting higher affinity to iron(III) than other tridentate iron(III) 
chelators and show anti-proliferative activity. The critical role of iron binding is further 
confirmed by the low cytotoxicity of the iron (III)-triazine complex.28 
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The unavailability of an animal model that reflects pathological conditions observed in post-
mortem AD human brains and the lack of reliable biomarkers to detect and understand the 
progression of AD are considered to be major challenges in AD drug discovery.29 Therefore, AD 
requires multi-factorial treatments that perform multiple tasks such as reducing inflammation, 
preventing of Aβ and tau aggregation, and increase antioxidant capacity.30 Although the 
development of Aβ-modulating agents are underway, still there is no perfect drug or effective 
treatment of AD and many drugs have failed in recent clinical trials.31  In order to tackle the 
problem, effective therapeutic and preventive interventions need to be developed urgently. Based 
on the importance of EGCG polyphenol binding and triazine derivatives in inhibition of Aβ 
aggregation, herein, we rationally designed and synthesized (Scheme 4.9a, b, c, d, 4.10a, b and 
4.11) a series of triazine scaffolds containing a polyphenol skeleton in order to investigate their 
ability to inhibit, prevent/alter Aβ protein aggregation and self-assembly.32 It is expected that 
these compounds could also protect against neurodegeneration through their antioxidant and 
metal chelation properties.33 
s-Triazine (Figure 4.6) is a heterocyclic compound with three nitrogens situated at 1st, 3rd and 5th 
positions. Its analogues, cyanuric chloride, melamine, substituted aryl nitriles and cyanuric acid 
are important starting materials for various products with wide range of applications in 
pharmaceuticals, textile, polymer and rubber industries. Additionally, these compounds have 
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found applications as pesticides, dyestuffs, optical bleaches, in explosives and as surfactants. The 
attractive properties of the 1,3,5-triazine scaffold include is symmetrical, monocyclic and non-
polar core form that provides the basis for the design of biologically relevant molecules with 
widespread therapeutic applications. 
 
4.6 Synthetic approaches to 2,4,6-substituted -1,3,5-triazine derivatives 
As proposed by Sander and coworkers in 1988, the formation of s-triazines initially involves the 
reaction between ammonia and nitriles under lanthanide catalysis to produce a mono-substituted 
amidine intermediate 85 (Scheme 4.2).34 Subsequent reaction of 85 with two additional 
molecules of the nitrile followed by cyclisation and loss of ammonia produces the different 
2,4,6-trisubstituted-1,3,5-triazine 86. The Ln3+ ion polarizes the cyano group through an ion-
dipole interaction to promote the addition of ammonia in 72-95% yields. The reaction is carried 
out at high temperatures of 200 oC due to formation of pyrimidines as temperature dependent by 
products. 
 
Shen and coworkers documented that (Scheme 4.3) the cyclotrimerization of both unsubstituted 
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and substituted aromatic nitriles as well as heteroaromatic nitriles are effectively catalyzed by 
SmI2 at 80 
oC to give the corresponding 2,4,6-trisubstituted-s-triazines in 45-99% yield. 35 
 
Also, the cyclotrimerization reaction of aryl nitriles using excess triflic acid (Scheme 4.4) from 0 
oC to room temperature under an argon atmosphere provides various 2,4,6-trisubstituted s-
triazines in 70-90% yield.36 
 
The multistep synthesis of unsymmetrical 1,3,5-triazine derivatives (88 and 89) was reported 
(Scheme 4.5) by Tigelaar et al., in 2009.37 The synthesis involves reaction of cyanuric chloride 
with Grignard reagents38 followed by reaction with N,N-di substituted phenyl/alkyl amines to 
generate aromatic and aliphatic substituted unsymmetrical 1,3,5-triazine derivatives.39,40 
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In 2009 Yu and co-workers published the solid-phase synthesis using the “teabag” 
methodology.41,42 The amine was attached to the N-benzyl-4-(4-formyl-3-
methoxyphenoxy)butanamide 90 in the presence of NaBH3CN in DMF/AcOH reductive 
amination to give 91. Subsequently this resin-bound amine 91 by nucleophilic substitution was 
selectively captured as the monoarylsubstituted triazine 92 to give product 93. Then cleavage of 
resin was accomplished  from 93 by (i) heating in DMF with amines at 100 °C and (ii) by 
treatment with 50% TFA in DCM to produce  2,4-diamino-6-aryl-1,3,5-triazines 94 (Scheme 4.6). 
Product yields were highly variable ranging from 52-83% and depended on the nature of 
substituent groups. 
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Alvarez et al., proposed that the reaction between equimolecular amounts of a nitrile and triflic 
anhydride or triflic acid at low temperature produces an intermediate nitrilium salt that 
subsequently reacted with 2 equivalents of a nitrile at higher temperatures to form substituted 
unsymmetrical 1,3,5-triazines in moderate 39-82% yields (Scheme 4.7).43 
 
 
Eisler and coworkers synthesised functionalized symmetrical poly hydroxy/methoxy aryl 
substituted triazines via the Friedel-Crafts arylation method by using a Lewis acid (AlCl3) at 
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reflux temperatures. In this method purification of the product by column chromatography was 
unnecessary and low to high variable yields 19 to 96% (Scheme 4.8) were generally obtained. 44 
 
4.7 Results and Discussion 
Although, the methods discussed above have contributed to the construction of the 1,3,5-triazine 
skeleton, unfortunately most of the methods require high reaction temperatures and considerable 
purification of the products. So despite the quick one step assembly of most of these analogs, the 
synthesis of 2,4,6-trisubstituted polyphenol 1,3,5-triazines continues to be a useful task. In view of 
the many medicinal applications and demand for this core ring/skeleton, alternative method of 
synthesis of triazines is highly desirable. Besides making use of the existing methods for the 
synthesis of triazine analogues, we also examined readily scalable and versatile novel approaches 
for the construction of analogues. 
4.7.1 Method I: Cyclotrimerization  
Compounds (96a-e) were prepared by the following reported procedure36 outlined in Schemes 
4.9a, b, c and d. The cyclotrimerization of commercially available substituted aryl nitriles (95a-f) 
was performed with different molar ratios (1.2 to 10 equiv.) of triflic acid at 0 oC to 91 oC 
temperatures. We found the optimal temperature range to be 10 ° to 50 °C and the reaction times 
of 5 to 13 h produced 59-85% yields of various substituted triazines.  
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We attempted the one-pot synthesis of 2,4,6-tris-(4-formylphenyl)-1,3,5-triazine 97 from 96a. 
This is a reported procedure for the synthesis of tris(4-formylphenyl) triazine by Vilsmeier-Haack 
formylation45 reaction (Scheme 4.9a) with POCl3/DMF (25-40 equiv of  POCl3 at 85-100 
oC for 
12 – 48 h) different variable reaction conditions, but were unable to prepare product 97. Only 
decomposed starting material was observed by TLC reaction monitoring. 
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4.7.2 Method II: Friedel-Crafts arylation  
The Friedel-Crafts arylation reaction is the method of choice for attaching bulky aryl substituents 
to the triazine core (Scheme 4.10a and b). 46 Compound 98b can be formed in one step from the 
readily available starting material resorcinol 99 through reaction with AlCl3 and cyanuric chloride 
100 in 1,2–dichloroethane under reflux in 73% yield.47 Motivated by this result, 98c was prepared 
from cyanuric chloride when treated with phloroglucinol 101. Due to low solubility of 101 we 
used a mixture of DCM and ether was refluxed for 12 h to give an isolated 96% yield as reported. 
Both 98b & 98c products are highly insoluble in most of organic solvents, so purification was 
performed via a centrifuge wash and drying process.44 Compound 98a was prepared directly48 
from cyanuric chloride 100 dissolved in phenol and refluxed for 5 h provide 98a in 82% yield. 
Phenol is bidentate nucleophile, involved in two pathways are C-arylation forms slowly under 
thermodynamic control using AlCl3 (Lewis acid) and O-arylation forms faster under kinetic 
control. So that, it is certainly promoted by the Lewis acid properties of AlCl3, but the activation is 
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by co-ordination at the triazine nitrogen, then promoting nucleophilic attack at the C=N double 
bond rather than by abstraction of chloride to give a carbocation. 
 
 
The 3,4,5-trimethoxy phenol 103 was synthesised primarily from 3,4,5-trimethoxy benzaldehyde 
102.49 Then followed several attempted Friedel-Crafts arylation reactions of 103 with AlCl3 and 
cyanuric chloride 100 in 1,2–dichloroethane under 12 h reflux conditions. All attempts resulted in 
the isolation of 2,4,6-tris(3,4,5-trimethoxyphenyloxy)-1,3,5-triazine 98e and not the anticipated 
98d (Scheme 4.11).44 Here O-arylation predominates in the product formation over the C-arylation 
due to electron withdrawing groups formation of a unsterilized resonance structures.  
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Furthermore our efforts to synthesize the polyphenol triazines by the cyclotrimerisation36 of nitrile 
precursors 104 and 106 under CF3SO3H with various temperatures and reaction times were 
unsuccessful and starting material was recovered (Scheme 4.12 & 4.13). All the reagents and 
reaction conditions investigated as shown in Table 4.2 were also fruitless 
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Table 4.2 Experimental conditions for the attempted synthesis of substituted 1,3,5-triazines  
Entry Starting material                 Reaction condition    Product/ result 
1 104    CF3SO3H, 0 
oC- 100 oC, 12 - 28 h.     No reaction 
2 104 CF3SO3H, CHCl3, 0 
oC- 55 oC, 12 - 24 h.     No reaction 
3 106 CF3SO3H, CHCl3, 0 
oC- 50 oC, 12 - 24 h.     No reaction 
4 106      CF3SO3H, 0 
oC- 100 oC, 12 - 28 h.     No reaction 
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4.8 Biological studies 
4.8.1 In vitro cytotoxicity 
All the synthesized compounds were tested (except 96a, b due to their insolubility in 
DMSO) for their cytotoxicity against three human tumor cell lines including lung (A549), 
breast (MDA-MB-231) and fibro sarcoma (HT1080) cells using standard MTT assays.50 
 The doses required to inhibit 50% cancer cell growth was represented as IC50 values (µM) 
in Table 4.3. The results from the table indicated that two compounds, Compound 96d and 
compound 98b with a number of hydroxyl groups displayed significant growth inhibition 
on all the three tested cancer cells with IC50 values in the range of 6.05-14.76 µM and were 
higher in comparison to EGCG (22.3-36.5 µM). The compound 96d displayed significant 
growth inhibition on A549 and HT1080 cells with the IC50 values of 6.98 and 8.58 µM 
respectively. The remaining compounds were considered to be inactive as their IC50 values 
were more than 50 µM. As the compounds 96d, 98b displayed selective cytotoxicity on 
A549 cells. It was of interest to investigate their mechanism of cell growth inhibition. 
Table 4.3:  In vitro anticancer activity (aIC50- µM) of the compounds 96c, b, d -98a, b, c. 
50% inhibitory concentration and mean ± SD of three individual experiments performed in 
triplicate.  
Compound A549 (lung) MDAMB-231 
(breast) 
 
HT1080 (fibro 
sarcoma) 
96d 6.98 ±1.07 >50 8.58 ± 1.53 
98b 11.18 ± 2.48 6.05 ± 0.86 14.7 ± 2.21 
98c >50 >50 >50 
98a,d >50 >50 >50 
96c >50 >50 >50 
96b >50 >50 >50 
96a, b nd nd nd 
EGCG 22.3±4.62 36.5±3.98 >50 
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4.8.2 Cell cycle analysis 
 
12d - C21H15N3O3 (96d); 13b-C21H15O6N3 (98b) 
Figure 4.7 The effect of compounds 96d and 98b on cell cycle distribution. A549 cells 
were treated with IC50 concentrations of the compounds 96d and 98b for 48 h and stained 
with propidium iodide and analyzed through flow-cytometer. 
It is established that deregulation of cell cycle events leads to uncontrollable proliferation 
and then to tumorigenesis.51 Therefore, chemotherapeutics that can target the cell cycle are 
effective in inhibition of cancer progression.52 In order to investigate the effect of 
compounds 96d and 98b on cell cycle distribution of A549 cells, we have carried out flow-
cytometry experiments. In this assay, A549 cells were treated with the compounds 96d, and 
98b for a period of 48 h, stained with propidium iodide and cells were analyzed for DNA 
content through flow-cytometry. The results from Figure 4.7 indicated that the untreated 
control cells display 66.9 % cells in G1 phase, whereas compound 96d and 98b treatments 
resulted in decrease in G1 phase to 25.7% and 30.1% respectively and simultaneous 
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increase in DNA content in S and G2/M phases. The compound treatment resulted in 
significant increase in cells in G2/M phase that are 26.7% and 21.4% respectively in 
comparison to the control 7.62% (Figure 4.7). These results showed compounds induced 
cell cycle arrest is also contributing to the toxicity of the compounds. 
4.8.3 Hoechst staining 
Apoptosis is a programmed cell death and plays an important role in tissue development 
and homeostasis. Deregulation of apoptotic pathways results in many diseases including 
cancer.53 Moreover most of the chemotherapeutic drugs act by activating the apoptotic 
pathways. Therefore, it was considered of interest to investigate the apoptotic inducing 
effect of compounds 96d and 98b on A549 cells using Hoechst 33242. Which is blue 
fluorescent DNA binding dye that emits strong bright blue fluorescence λ upon binding to 
the apoptotic cell nuclei because of chromatin condensation. Hoechst staining was 
performed on A549 cells after 48 treatments with the compounds 96d and 98b. As shown 
in Figure 4.8, the compound 96d and 98b treated cells displayed bright and fragmented 
nuclei due to the chromatin condensation and fragmentation, in contrast the control cells 
display nuclei with uniform shape and color (Figure 4.8) These results demonstrate the 
compound 96d and 98b could induce apoptosis in A549 cells. 
Figure 4.8 96d and 98b induced nuclear morphological changes in A549 lung cancer cells. 
 
 
 
 
 
Control 96d 98b 
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4.9 Antioxidant Capacity of 98b, c using the 1,1-diphenyl-2-picrylhydrazyl Radical 
(DPPH) Spectrophotometric Assay 
The DPPH assay method 54 is based on the reduction of DPPH, a stable free radical. The free 
radical DPPH with an odd electron gives a maximum absorption at 517 nm (purple colour). 
When Antioxidants react with DPPH, which is a stable free radical becomes paired off in the 
presence of a hydrogen donor (e.g., a free radical-scavenging antioxidant) and is reduced to 
the DPPHH and as consequence the absorbance decreased from the DPPH. Here we tested 
all the hydroxyl polyphenols (96d, e, 98b and c) for DPPH scavenging activity, in that only 
98b, c compounds showed the activity. The methanol solution of 98b, c demonstrated 
appreciable antioxidant activity relative to the reference values of ascorbic acid with DPPH 
radical scavenging method. At the lowest concentration (0.2 mM), 98c exhibited a mean 
antioxidant activity of 50% and 98b showed 23% while ascorbic acid produced 33% (Figure 
4.9). However, at the highest concentration (2mM), the 98c and 98b had 58% antioxidant 
activity compared to 52% with ascorbic acid at the same concentration. 
 
Figure 4.9 The antioxidant activity of compound 98c and 98b with DPPH 
spectrophotometric assay 
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4.10 MTT cell viability assay for Aβ-toxicity55 
MTT viability assay is commonly used to evaluate Aβ toxicity. We appreciate and 
acknowledge that this assay was performed by postgraduate student Maria Del Castillo 
Frias, from the research laboratory of Professor Doig at Manchester University, UK. The 
analysis of the reduction of yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) to purple formazan by mitochondrial dehydrogenases indicates the 
viability of the culture. 
Results  
Figure 4.10a: Cells treated with Aβ (1-42) 1µM and drugs at 5µM. According to the 
results drugs 96d, 98b and 98a in combination with Aβ (1-42) are not affective as anti-
amyloidogenic agents. 98c ameliorates toxicity caused by Aβ (1-42) significantly p<0.001).  
Figure 4.10b: Comparing the viability of drugs at 5µM with cells non-treated, with 
compounds 96d, 98b and 98a considered ineffective in combating Aβ toxicity at this 
concentration.  
no
n-
tr
ea
te
d
A
 
1
M A
3
A
4
A
6
A
7
A
8
0
50
100
150
%
 o
f 
c
e
ll
 v
ia
b
il
it
y
**
**
********
no
n-
tr
ea
te
d
A
1
M A
3
A
4
A
6
A
7
A
8
0
50
100
150
%
 o
f 
c
e
ll
 v
ia
b
il
it
y
**
**** ****
a) b)
 
A3- C21H15N3O3 (96d); A4-C21H15O6N3 (98b); A6-C21H15N3O3  (98a); A7-C30H33N3O12 
(98e); A8-C21H15N3O9 (98c) 
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Discussion  
The polyphenol-s-triazines 98c, 98e ameliorates toxicity caused by Aβ (1-42).  It may be 
that the reason of the toxicity of compounds 96d, 98b and 98a is solubility/concentration 
dependent, so that a decrease of their concentration may better assess the effect of these s-
triazines in cells treated with Aβ (1-42).   
4.11 EXPERIMENTAL 
4.11.1 2,4,6-Triphenyl-1,3,5-triazine (96a)  
 
Benzonitrile 95a (Scheme 4.9a) (0.5 g, 4.85 mmol) was added dropwise to a stirred 
solution of trifluoromethanesulphonic acid (1.71 mL, 19.4 mmol) at 0 oC and then 
temperature raised up to 91 oC for 12 h. When the reaction mixture cooled to temperature, 
the yellow solution was poured into water (10 mL) formed a white precipitate. 
Recrystallization of this precipitate from chloroform (15 mL)  afforded 96a as white 
crystals (0.98 g, 66%). m.p. 230 o–234 oC (reported m.p.56 232 oC); 1H NMR (300 MHz, 
CDCl3): δ 8.81 (dd, J = 8.0, 1.5 Hz, 6H), 7.62-7.56 (m, 9H), 13C NMR (100 MHz, CDCl3): 
δ 171.6, 136.2, 132.5, 128.9, 128.6,; HRMS: m/z calcd for C21H15N3H [M+H]+: 309.1296; 
found: 310.1373. 
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4.11.2 2,4,6- Tris-p-tolyl-1,3,5-triazine (96b) 
 
p-Tolunitrile 95b (Scheme 4.9b) (0.6 g, 5.1 mmol) was treated with small portions (1.35 
mL, 15.3 mmol) of trifluoromethanesulfonic acid at 25-35 oC then stirred for 13 h. The 
dark brown reaction mixture was poured on ice and neutralized with ammonium hydroxide. 
The insoluble precipitate was filtered off and washed with acetone to give white solid (2.2 
g). After recrystallization from toluene gave 2,4,6-tri-p-tolyl-s-triazine 96b (1.14 g, 64%) 
as white crystals m.p. 280 o-284 oC (reported m.p.57 283 o-285 oC). 1H NMR (300 MHz, 
CDCl3): δ 8.66 (d, J = 8.6 Hz, 6H), 7.37 (d, J = 7.3 Hz, 6H), 2.5 (s, 9H); 13C NMR (100 
MHz, CDCl3): δ 171.4, 142.9, 133.7, 129.3, 128.9, 21.7; HRMS: m/z calcd for C24H21N3: 
351.1735; found [M+H]+: 352.1825. 
4.11.3 2,4,6-Tris(4-methoxyphenyl)-1,3,5-triazine (96c) 
 
p-Methoxybenzonitrile 95c (Scheme 4.9c) (0.3 g, 2.25 mmol) was added in small portions 
to (1.18 mL, 7.89 mmol) trifluoromethanesulfonic acid at 0 o-15 oC, then stirred for 5 h 
formed a thickened  black colour mixture that was poured onto ice followed by 
neutralization with ammonium hydroxide. The reaction mixture was diluted with CH2Cl2 
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(15 mL) and washed with water (20 mL), and brine (15 mL), dried (Na2SO4) and 
concentrated in vacuo. The crude solid was purified by column chromatography (Silica gel 
60-120 mesh, EtOAc:n-hexane, 25:75) to afford 96c (0.52 g, 59%) as a white solid. m.p. 
217 o-221 oC (reported m.p.58 214 o-216 oC); 1H NMR (300 MHz, CDCl3): δ 8.73 (d, J = 
8.7 Hz, 6H), 7.05 (d, J = 7.0 Hz, 6H), 3.94 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 170.7, 
163.1, 130.7, 129.1, 113.8, 55.4; HRMS: m/z calcd for C21H21N3O3 : 399.1583; found 
[M+H]+: 400.1642. 
4.11.4  2,4,6-Tris(4-hyroxy phenyl)-1,3,5-triazine (96d) 
 
p- hydroxybenzonitrile 95d (Scheme 4.9c) (0.3 g, 2.52 mmol) was added in small portions 
to (0.88 mL, 10.08 mmol) trifluoromethanesulfonic acid at 0 oC and then the temperature 
raised up to 60 oC for overnight, the resulting brick red colour mixture was poured onto ice 
water to form a white precipitate after neutralization with ammonium hydroxide under cool 
condition. The mixture was diluted with ethyl acetate (20 mL), and the mixture was 
allowed to stir until two clear layers were obtained (1 h). The two layers were separated. 
The organic layer was washed with brine (20 mL) dried (Na2SO4), and concentrated in 
vacuo. The crude solid was purified by column chromatography (Silica gel 60-120 mesh, 
EtOAc: n-hexane, 50:50) to yield compound 96d (0.76 g, 85%) as colorless solid. m.p 252-
254 oC (reported m.p.59 >250 oC). 1H NMR (300 MHz, CD3OD): δ 8.57 (d, J = 8.5 Hz, 
6H), 6.98 (d, J = 6.9 Hz, 6H); 13C NMR (100 MHz, CD3OD): δ 170.7, 161.5, 130.4, 127.6, 
114.9; HRMS: m/z calcd for C21H15N3O3: 357.1113; found [M+H]
+: 358.1002. 
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4.11.5  2,4,6-Tris-(2-hydroxyphenyl)-1,3,5-triazine (96e) 
 
o-Hydroxybenzonitrile 95f (Scheme 4.9d) (0.3 g, 2.52 mmol) was added in small portions 
to (0.88 mL, 10.08 mmol) trifluoromethanesulfonic acid at 0 oC and then the temperature 
raised up to 55 oC for overnight, formed a brick red colour mixture and that mixture poured 
in to ice water forms a white precipitate, neutralization with ammonium hydroxide. The 
reaction mixture was diluted with ethyl acetate (15 mL) and washed with water (20 mL), 
and brine (15 mL), dried (Na2SO4) and concentrated in vacuo. The crude solid was purified 
by column chromatography (Silica gel 60-120 mesh, EtOAc:n-hexane, 55:45) to afford 96e 
(0.71 g, 80%) as a light yellow solid. m.p. 311o-317 oC (reported m.p.60 307 o-309 oC); 1H 
NMR [300 MHz, CDCl3: CD3OD (95:5)]: δ 12.37 (br, 3H), 7.56 (d, J = 7.9 Hz, 2H), 7.24-
7.30 (m, 2H), 6.83 (d, J = 8.3 Hz, 2H), 6.74 (t, J = 7.6 Hz, 2H); 13C NMR [100 MHz, 
CDCl3: CD3OD (95:5)]: δ 172.5, 161.4, 134.1, 127.7, 118.4, 117.8, 114.1; HRMS: m/z 
calcd for C20H24O6 : 357.1115; found [M+H]
+:  358.1189. 
4.11.6  2,4,6-Triphenoxy-1,3,5-triazine (98a) 
 
Commercially available (Scheme 4.10a) cyanuric chloride 100 (0.5 g, 2.71 mmol) was 
dissolved in phenol (1.02 g, 1.08 mmol) and the mixture was refluxed for 5 h. In the hot 
reaction mixture a white solid was directly formed that the indicated of the completion of 
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the reaction. This white solid was directly extracted with methanol and concentrated in 
vacuo to afford 98a (0.78 g, 82%). m.p.: 234 - 239 oC (reported m.p.61 235 o-236 oC); 1H 
NMR (300 MHz, DMSO-d6): δ 7.41 (br, 6H), 7.24 (br, 9H). MS m/z: [M+H]+: 355. 
4.11.7 2,4,6-Tris (2,4- dihydroxy phenyl)-1,3,5-triazine (98b) 
 
A mixture (Scheme 4.10b) of cyanuric chloride 100 (0.3 g, 1.63 mmol) and resorcinol 99 
(0.55 g, 5.06 mmol) in dry 1,2-dichloroethane (10 mL) was allowed to stir for 15 min at 75 
ºC to dissolve the solids. Then reaction was cooled to 0 oC and anhydrous aluminum 
chloride (0.69 g, 5.21 mmol) was added portion wise. The reaction mixture was heated to 
60 oC for 15 h. After the reaction mixture cooled to room temperature the solvent was 
removed under vacuo. The solid was suspended in water (10 mL) and centrifuged at 3400 
rpm for 5 min, then again that solid was suspended in water and it was repeated two times 
with distilled water. Finally the pellet was triturated with diethyl ether to remove unreacted 
resorcinol. Then the solid was dissolved in ethanol and concentrated under vacuo to afford 
a 98b (0.48 g, 73%) as a dark yellow solid (m.p. >300).44 1H NMR (300 MHz, DMSO-d6): 
δ 10.45 (br, 3H), 8.12 (d, J = 8.0 Hz, 3H), 6.51- 6.33 (m, 6H); 13C NMR (100 MHz, 
DMSO-d6): δ 168.3, 164.4, 163.6, 131.7, 109.4, 107.3, 103.5; HRMS: m/z calcd for 
C21H15N3O6: 405.0961; found [M+H]
+: 406.0826. 
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4.11.8   2,4,6-Tris (2,4,6- trihydroxy phenyl)-1,3,5-triazine (98c) 
 
A reaction mixture (Scheme 4.10b) of cyanuric chloride 100 (0.2 g, 1.08 mmol) and 
phloroglucinol 101 (0.42 g, 3.36 mmol) was stirred in a solution of 1:4 dry CH2Cl2 and 
diethyl ether (10 mL). After dissolving of starting materials, anhydrous aluminum chloride 
(0.38 g, 3.47 mmol) was added portion wise at 0 oC and then reaction heated to reflux for 
overnight. The solvent was removed under vacuo and the solid was suspended in 10% HCl. 
The colloidal solution was centrifuged (3400 rpm for 5 min), supernatant was removed and 
the pellet was resuspended in distilled water and the centrifugation was repeated two times. 
Finally the pellet was triturated with diethyl ether to remove unreacted phloroglucinol. 
Then the solid was dissolved in ethanol and concentrated under vacuo to afford a 98c (0.46 
g, 96%) as an orange red solid.44 m.p >200 °C; 1H NMR (300 MHz, DMSO-d6): δ 12.3 (br, 
6H), 10.14-10.18 (br, 3H), 5.88 (s, 6H); 13C NMR (100 MHz, DMSO-d6): δ 165.8, 164.6, 
163.5, 98.2, 95.7, 56.5; HRMS: m/z calcd for C21H15N3O9H [M+H]
+: 453.0808; found: 
454.1066. 
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4.11.9 3,4,5-Trimethoxyphenol (103)49 
 
A solution of 3,4,5-trimethoxybenzaldehyde (102) (2.00 g, 10.2 mmol) in dry DCM (20 
mL) was cooled to 0 oC followed by the addition of MCPBA (2.64 g, 15.3 mmol) portion 
wise over 30 min. After stirring for 1 h the cold bath was removed and the reaction was 
allowed to stir at room temperature for a further 8 h. Filtration of the mixture followed 
washing with NaHCO3 and evaporation gave the formate ester in 60% yield as indicated by 
GC-MS. The crude material was dissolved in MeOH (10 mL) and cooled to 0 oC followed 
by the addition of KOH (0.5 g). After stirring for 30 min at room temperature, the solvent 
was evaporated and the residue washed with hexane, dissolved in water (100 mL), filtered 
then acidified with HCl at 0 oC. After standing for 30 min, a white solid was filtered and 
dried to provide the target compound 103 (1.12 g, 60%) as an off white powder. m.p. 145-
146 oC; 1H NMR (300 MHz, CDCl3): δ 6.09 (s, 2H), 5.57 (br. s, 1H), 3.79 (s, 3H), 3.77 (s, 
6H); 13C NMR (75 MHz, CDCl3): δ 153.7, 152.5, 131.6, 92.9, 61.0, 55.9.  
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4.11.10 2,4,6-Tris(3,4,5-trimethoxyphenyloxy)-1,3,5-triazine (98e)44 
 
A solution of 3,4,5-trimethoxyphenol 103 (0.546 g, 2.78 mmol) and cyanuric chloride 100 
(0.143 g, 0.78 mmol) in 1,2-dichloroethane (70 mL) was cooled to 0 oC. Anhydrous AlCl3 
(0.315 g, 2.36 mmol) was added portion wise over 10 min and the mixture heated at reflux 
overnight under a nitrogen atmosphere. The reaction was quenched by the addition of water 
(30 mL) and DCM (30 mL) and allowed to stir briefly before shaking vigorously in a 
separating funnel. The organic layer was removed and the aqueous layer extracted with 
DCM (3 x 60 mL). The combined organic extracts were washed with water (2 x 50 mL), 
dried with MgSO4 then concentrated to leave a yellow solid. Trituration in EtOAc  was 
followed by filtration and air drying gave the unexpected product i.e. 2,4,6-tris(3,4,5-
trimethoxyphenyloxy)-1,3,5-triazine 98e (0.516 mg, 29.8%) as a light yellow powder. m.p. 
282 oC (dec.) [and not the expected Friedel Crafts C-arylated product (98d)]. 1H NMR (300 
MHz, CDCl3): δ 5.57 (s, 6H), 3.52 (s, 18H), 3.22 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 
186.8, 175.1, 167.1, 104.3, 80.6, 56.0, 52.8. FTIR (KBr, ν cm-1) 2985.8 (w), 2950.0 (w), 
2848.3 (w), 2832.0 (w), 1667.1 (s), 1636.4 (m), 1604.5 (s), 1541.8 (s), 1458.2 (m), 1354.2 
(s), 1242.6 (m), 1210.4 (s), 1180.1 (w), 1117.8 (m), 1097.6 (s), 1084.1 (s), 1001.6 (w), 
858.1 (w). ESI HRMS m/z calcd for C30H33N3O12 [M+H]
+: 628.2136,  found 628.2176. 
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4.12 Biology 
4.12.1 Cell Culture 
A549 (lung), MDAMB-231 (breast) and HT1080 (fibro sarcoma) cells were procured from 
ATCC. A549 and MDAMB-231 cells were maintained in RPMI (Roswell Park Memorial 
Institute)-medium, and HT1080 cells were grown in DME (Dulbcco’s Modified Eagle) 
medium supplemented with 10% fetal bovine serum and 1% pencillin-streptomycin 
(GIBCO). All the cells were maintained at 37 oC with relative humidity of 85%. Cells were 
subcultured using 0.25% trypsin-EDTA every 2-3 days at no less than 85% confluency.  
4.12.2 MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay 
MTT is the standard method for determining the cell viability and proliferation. In this 
assay, A549, MDAMB-231 and HT1080 cells were seeded in 96 well cell culture plates 
depending on their doubling times and allowed to adhere overnight. Then, the growth 
medium was removed from the wells and cells were treated with medium containing 
different concentrations (100 µM - 0.01 µM) of the test compounds (1-6) for a period of 72 
h at 37 oC. The medium containing compounds was removed after 72 h and MTT solution 
(0.5 mg/mL) in serum free medium was added to each well and further incubated for 4 h at 
37 oC. Then, the excess unreacted MTT solution was removed and the obtained reduced 
formazan crystals were solubilized by adding 100 µL DMSO. The absorbance of the 
resulting colored solutions was read at 570 nm using plate reader and the IC50 values were 
calculated using probit software.62 
4.12.3 Cell Cycle 
The effect of compounds 96d and 98b on cell cycle distribution of A549 cells was 
determined using propidium iodide staining. Briefly, A549 cells were seeded in 6 well 
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plates at a density of 2x 105 cells /mL and allowed to grow overnight. Cells were collected 
by trypsinisation after treatment with IC50 concentrations of the compounds 96d and 98b 
for a period of 48 h and washed with PBS and fixed with 70% cold ethanol. The fixed cells 
were kept at 4 oC for 30 min and washed with PBS before staining with propidium iodide. 
The cells were incubated at room temp for 30 min and analyzed through flow-cytometer 
(BDc6-Accuri).63 
4.12.4 Hoechst Staining 
A549 cells were grown on coverslips at a density of (2X105 cells/mL) in a 6 well plate and 
allowed to adhere overnight. Cells were treated with IC50 concentrations of the compounds 
96d and 98b for a period of 48 h. After the treatment, cells were washed with PBS and 
fixed with 4 % para formaldehyde and stained with Hoechst 33242 (2 µg/mL) for 20 min at 
37 oC. The excess dye was washed three times with PBS and cells were observed for 
nuclear morphological changes under confocal microscope (Nikon) using blue filter.64 
4.13 DPPH Spectrophotometric Assay 
0.2 mL of the test compounds (98b, c) at concentrations ranging from 0.2 mM to 2 mM 
was each mixed with 1.8 mL of 0.1 mM DPPH (in methanol) as well as 0.2 mL standard 
compound (Ascorbic acid) were taken in 0.2 mM to 2 mM concentrations and volume 
made uniformly to the methanolic solution of 1.8 mL of 0.1 mM DPPH. The four different 
concentrations of each testing sample were prepared. Absorbance was taken after 15 min. 
at 517nm using methanol as blank on UV-visible spectrometer Shimadzu, UV-1601, Japan. 
The percentage antioxidant activity was calculated using the following formula.65 
% scavenging = [Absorbance of control - Absorbance of test 
sample/Absorbance of control] X 100 
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4.14 MTT cell viability assay for Aβ-toxicity 
MTT viability assay is commonly used to evaluate Aβ toxicity.54 The reduction of yellow 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to purple formazan 
by mitochondrial dehydrogenases indicates the viability of the cell culture.   
At 70-80% confluence, SH-SY5Y cells were harvested from flasks by trypsinisation and 
re-suspended in Opti-MEM medium supplemented with 1.5% FBS, 1% L-Q, 1% P/S and 
1% n-aa. The cells were seeded at 3 x 104 cells/well in a 96- well polystyrene plate and 
incubated overnight at 37 °C, 5% CO2 to allow cell attachment to the surface. Each well 
was replenished with 100 μL of Opti-MEM medium containing 0.35% DMSO the test 
compounds at 5µM and 1µM Aβ (1-42). In addition, negative control wells were 
replenished with 100 μL of Opti-MEM 0.2% DMSO. Each experimental group was done in 
triplicate.  The 96-well polystyrene plate was incubated 24 h at 37 °C, 5% CO2.  Ten 
minutes prior to cell viability evaluation, negative controls were replenished with 100 μL 
of 0.1% Triton X. 50 μL of medium were removed and 10 μL of sterile MTT (2.5mg/ml) 
was added to all wells. Then the plate was incubated for 3hr at 37°C, 5% CO2. Formazan 
produced by cells was solubilized by adding 100 μL of acid-isopropanol (stock solution 
100ml of isopropanol and 398 μL of HCl 37%). The absorbance of the plates was measured 
using a Polarstar BMG labtech plate reader at 570nm. Percentage of MTT reduction (cell 
viability) was calculated as:  
Where X is the absorbance value of each well, A is the mean absorbance of the negative 
control, and B is the mean absorbance of the positive control.  
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4.18 Supporting Information of different 2,4,6-trisubstituted s-
triazines 
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1H NMR Spectrum of compound 96a in CDCl3 (300 MHz) 
 
13CNMR Spectrum of compound 96a in CDCl3 (300 MHz) 
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1H NMR Spectrum of compound 96b in CDCl3 (300 MHz) 
 
13CNMR Spectrum of compound 96b in CDCl3 (300 MHz) 
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158  
 
 
 
1H NMR Spectrum of compound 96c in CDCl3 (300 MHz) 
 
13CNMR Spectrum of compound 96c in CDCl3 (300 MHz) 
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159  
 
 
 
1H NMR Spectrum of compound 96d in MD3OD (300 MHz) 
 
 
13CNMR Spectrum of compound 96d in MD3OD (300 MHz) 
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1H NMR Spectrum of compound 96e in CDCl3: MD3OD (95:5) (300 MHz) 
 
13CNMR Spectrum of compound 96e in CDCl3: MD3OD (95:5) (300 MHz) 
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1H NMR Spectrum of compound 98b in DMSO-d6 (300 MHz) 
 
13CNMR Spectrum of compound 98b in DMSO-d6(300 MHz) 
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1H NMR Spectrum of compound 98c in DMSO-d6 (300 MHz) 
 
13CNMR Spectrum of compound 98c in DMSO-d6 (300 MHz) 
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2,4,6-Tris(3,4,5-trimethoxyphenyloxy)-1,3,5-triazine (98e) 
 
 
1H NMR (300 MHz) Spectrum of compound 98e in CDCl3 
 
 
13CNMR (70 MHz) Spectrum of compound 98e in CDCl3 
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Concluding statements 
In conclusion we have found efficient and highly flexible stereoselective synthesis catenioblin B 
and musacin F. This work describes the first total synthesis of catenioblin B via a titanium(IV) 
mediated regioselective epoxide ring-opening of an epoxy alcohol followed by Grignard reaction 
and Luche reduction to gave a hydroxy acid intermediate. Then follows the TEMPO/BAIB 
mediated intramolecular cyclization to form catenioblin B in 7.7% over all yield. In a similer 
fashion the structurally related musacin F synthesis was achieved via a series of Sharpless 
asymmetric dihydroxylation, Grignard reaction, Luche reduction and acid catalyzed 
intramolecular cyclization reaction in an overall yield 12.3 to 14.0%. 
On the other hand, among the series of 2,4,6-trisubstituted polyphenol-s-triazine molecules we 
prepared and tested against Alzheimer’s disease, compound 98c (A8) ameliorated the cellular 
toxicity Aβ. Also the antioxidant properties of 96d, 98b showed anti-cancer activities against 
three human cancer cell lines, with IC50 values in the range of 0.71-7.29 μM when compared 
with EGCG.  
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Future work 
There are many other analogues that merit preparation to generate an extensive library of poly- 
phenol triazines to investigate their anti-myloidogenic activities against Alzheimer’s disease. 
Synthesis of other isomers for more detailed studies about a structural revision of Musacin F 
towards the natural product structure. 
Focus on largely shifting toward the synthesis of molecules that have the potential for societal 
impact. 
 
 
